Page last updated: 2024-12-05

eflornithine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Eflornithine, also known as difluoromethylornithine (DFMO), is a medication used to treat African trypanosomiasis. It works by inhibiting the enzyme ornithine decarboxylase, which is essential for the synthesis of polyamines, molecules that are crucial for cell growth and proliferation. Trypanosomes, the parasites that cause African trypanosomiasis, rely heavily on ornithine decarboxylase for their survival. Eflornithine's ability to inhibit this enzyme effectively kills the parasites. It is also used to treat certain types of cancer, such as cutaneous T-cell lymphoma. Eflornithine is a synthetic compound that was first synthesized in the 1970s. It is given intravenously and has relatively few side effects, making it a valuable treatment option for these serious diseases. The drug is currently being studied for its potential use in other diseases, such as Alzheimer's disease and malaria.'

Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3009
CHEMBL ID830
CHEBI ID41948
SCHEMBL ID26327
MeSH IDM0000787

Synonyms (99)

Synonym
vaniqa
2-(difluoromethyl)ornithine
2-(difluoromethyl)-dl-ornithine
70052-12-9
dl-alpha-difluoromethylornithine
nsc-337250
nsc337250
dfmo hcl
dl-ornithine, monohydrochloride
.alpha.-dfmo hcl
HSCI1_000267
rmi 71782
2,5-diamino-2-(difluoromethyl)pentanoic acid
difluoromethylornithine ,
dfmo
ornidyl
dl-.alpha.-difluoromethylornithine
alpha-difluoromethylornithine
C07997
dl-ornithine, 2-(difluoromethyl)-
eflornithine
67037-37-0
CHEBI:41948 ,
alpha-(difluoromethyl)-dl-ornithine
difluromethylornithine
dfmo (growth regulator)
ornithine, 2-(difluoromethyl)-
alpha,delta-diamino-alpha-(difluoromethyl)valeric acid
mdl 71782
ccris 3295
eflornitina [spanish]
n-difluoromethylornithine
eflornithine [inn:ban]
dl-alpha-(difluoromethyl)ornithine
brn 2250529
eflornithinum [latin]
LOPAC0_000429
NCGC00162152-01
NCGC00015316-03
eflornithine (inn)
D07883
bdbm50028197
chembl830 ,
70050-56-5
AKOS006281180
rfi 7178
zqn1g5v6sr ,
eflornithinum
unii-zqn1g5v6sr
hsdb 7923
eflornitina
CCG-204521
NCGC00015316-02
FT-0630795
NCGC00015316-06
gtpl5176
2-(difluoromethyl)ornithine (dmfo)
.alpha.-difluoromethylornithine
eflornithine [who-dd]
eflornithine [inn]
eflornithine [mi]
eflornithine [vandf]
eflornithine [ema epar]
HY-B0744
SCHEMBL26327
2-difluoromethyl-2,5-diaminopentanoic acid
alpha-dfmo
DTXSID3020467 ,
(rs)-2,5-diamino-2-(difluoromethyl)pentanoic acid
DB06243
sr-01000076229
FT-0720946
2-(difluoromethyl)-l-ornithine
alpha-difluoromethyl-dl-ornithine
mfcd00221766
BCP10516
Q424751
(rs)-eflornithine
SDCCGSBI-0050414.P002
NCGC00015316-15
l-dfmo;l-rmi71782;l-alpha-difluoromethylornithine
FT-0775156
2-(difluoromethyl)-2,5-diaminopentanoic acid;
70052-12-9 (free base)
2,5-diamino-2-(difluoromethyl)pentanoic acid.
eflornithine free base
A936641
SR-01000076229-10
l-dfmo;l-rmi71782;l--difluoromethylornithine
EN300-150187
dl alpha difluoromethylornithine
alpha-difluoromethyl ornithine
alpha difluoromethyl ornithine
alpha difluoromethylornithine
ornithine, alpha-difluoromethyl
d11ax16
dtxcid70467
p01cx03
eflornithinum (latin)

Research Excerpts

Overview

Eflornithine 13.9% cream is a topical treatment that does not remove the hairs, but acts to reduce the rate of growth. The effect on facial hair growth starting to be seen from 1 month after treatment initiation.

ExcerptReferenceRelevance
"Eflornithine is a recommended treatment against late-stage gambiense human African trypanosomiasis, a neglected tropical disease. "( Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy.
Äbelö, A; Amilon, C; Ashton, M; Boberg, M; Jansson-Löfmark, R; Tarning, J, 2022
)
2.43
"Eflornithine 13.9% cream is a topical treatment that does not remove the hairs, but acts to reduce the rate of growth and appears to be effective for unwanted facial hair on the mustache and chin area."( Treatments for unwanted facial hair.
Lui, H; Shapiro, J,
)
0.85
"Eflornithine seems to be a better first-line therapy for treating late-stage Gambian trypanosomiasis in the Republic of the Congo."( Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo.
Balasegaram, M; Checchi, F; Ghorashian, S; Hamel, C; Harris, S; Karunakara, U, 2006
)
1.38
"Eflornithine is an effective treatment for unwanted facial hair in women, as reported by the patients."( The effect of eflornithine 13.9% cream on the bother and discomfort due to hirsutism.
Caro, G; Caro, JJ; Garfield, F; Huber, F; Jackson, J; Lin, CS; Schrode, K; Shander, D; Zhou, W, 2007
)
1.42
"Eflornithine 11.5% cream is an effective treatment for unwanted facial hair (UFH) in women with the effect on facial hair growth starting to be seen from 1 month after treatment initiation. "( A 4-month, open-label study evaluating the efficacy of eflornithine 11.5% cream in the treatment of unwanted facial hair in women using TrichoScan.
Hoffmann, R,
)
1.82
"Eflornithine is a specific, irreversible inhibitor of the enzyme ornithine decarboxylase which is thought to slow hair growth by inhibiting this enzyme in hair follicles. "( Topical eflornithine.
Balfour, JA; McClellan, K, 2001
)
2.19
"Eflornithine appears to be a useful salvage therapy in patients failing first-line treatments."( Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy.
Davies, S; Gazzard, B; Gleeson, J; Nelson, M; Smith, D; Youle, M, 1990
)
1.26
"Eflornithine is an antiprotozoal agent active against P."( Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a preliminary review.
Berry, AJ; Sahai, J, 1989
)
2.44

Effects

Eflornithine has been used on a compassionate basis in AIDS patients with PCP who were intolerant of or unresponsive to traditional agents.

ExcerptReferenceRelevance
"Eflornithine has been used to treat second-stage human African trypanosomiasis. "( Improving Eflornithine Oral Bioavailability and Brain Uptake by Modulating Intercellular Junctions With an E-cadherin Peptide.
Chen, Y; Feng, M; Rodriguez, L; Wang, MZ; Wu, JQ; Yang, S, 2019
)
2.36
"Eflornithine has been used on a compassionate basis in AIDS patients with PCP who were intolerant of or unresponsive to traditional agents."( Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a preliminary review.
Berry, AJ; Sahai, J, 1989
)
2.44

Treatment

Eflornithine, a topical treatment, is simple to apply and has minimal side effects. Treatment failed to reduce carotid arterial blood pressure and significantly elevated vascular pressure above and below the coarctation site.

ExcerptReferenceRelevance
"no eflornithine treatment (control) after 5-6 IPL-treatments in 22 women with facial hirsutism."( Adjuvant eflornithine to maintain IPL-induced hair reduction in women with facial hirsutism: a randomized controlled trial.
Haak, CS; Haedersdal, M; Philipsen, PA; Taudorf, EH; Vissing, AC, 2016
)
1.37
"Eflornithine, a topical treatment, is simple to apply and has minimal side effects."( Removal of unwanted facial hair.
Shenenberger, DW; Utecht, LM, 2002
)
1.04
"Eflornithine treatment failed to reduce carotid arterial blood pressure and actually significantly elevated vascular pressure above and below the coarctation site by 14 days of hypertension."( Multiple polyamine regulatory pathways control compensatory cardiovascular hypertrophy in coarctation hypertension.
Arcot, SS; Aziz, SM; Guo, H; Lipke, DW; Newman, PS; Olson, JW; Soltis, EE; Tofiq, S, 1997
)
1.02
"Eflornithine treatment consisted of 400 mg/kg/day intravenously for 14 days followed by 300 mg/kg/day orally for 21 days."( [A trial treatment with eflornithine of trypanosomiasis caused by Trypanosoma brucei gambiense in the Peoples Republic of the Congo].
Carme, B; Eozenou, P; Jannin, J; Ngampo, S; Schechter, PJ; Tell, GP,
)
1.16
"Treatment with eflornithine was effective."( Fever of unknown origin in an infant with an unexpected blood film report: a case report.
Dienye, PO; Gbeneol, PK,
)
0.47
"Treatment with eflornithine (Ornidyl) resulted in complete recovery."( [Sleeping sickness as an import pathology following a stay in Zaire].
Buyse, D; Van den Ende, J; Van den Enden, E; Vervoort, T, 1996
)
0.63

Toxicity

ExcerptReferenceRelevance
" This open trial shows that DFMO is as active as and possibly less toxic than melarsoprol."( Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness.
Ethier, L; Loko, L; Milord, F; Mpia, B; Pépin, J, 1992
)
0.59
" These results suggest that thrombocytopenia is the major dose-limiting side-effect of continuous DFMO infusion but does not occur at a dose of 500 mg/kg body wt/day."( Red blood cell polyamine levels and host toxicity during continuous alpha-difluoromethylornithine infusion.
Ajani, JA; Grossie, VB; Nishioka, K; Ota, DM; Stephens, LC, 1986
)
0.27
" Both drugs were judged too toxic to justify intrathecal or intraventricular studies with these agents in patients."( CNS toxicity and CSF pharmacokinetics of intraventricular DFMO and MGBG in beagle dogs.
Borcich, JK; Byrd, D; Campbell, J; Davis, RL; Levin, VA, 1984
)
0.27
"Ricin is a highly toxic protein produced by the castor bean (Ricinus communis)."( Modulation of ricin toxicity in mice by biologically active substances.
Muldoon, DF; Stohs, SJ,
)
0.13
" Furthermore, both toxic and nontoxic concentrations of glutamate stimulated the activity of ornithine decarboxylase (ODC)--the key regulatory enzyme in polyamine synthesis--and increased the concentration of ODC mRNA in cerebellar granule neurons but not in glial cells."( Induction of ornithine decarboxylase by N-methyl-D-aspartate receptor activation is unrelated to potentiation of glutamate excitotoxicity by polyamines in cerebellar granule neurons.
Bristol, LA; Guidotti, A; Lombardi, G; Manev, H; Szekely, AM, 1993
)
0.29
" These COX-2 and ODC inhibitor drugs were not overtly toxic at the doses used when administered to mice after weaning."( Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Cole, CE; Hawk, ET; Jacoby, RF; Kelloff, G; Lubet, RA; Newton, MA; Tutsch, K, 2000
)
0.31
" We have previously reported that amyloid beta-peptide (A beta), the main constituent of senile plaques in Alzheimer's disease (AD) brain, is toxic to neurons through a free radical-dependent oxidative stress mechanism and that A beta(1--42), the principal form of A beta in AD brain, causes an increase in polyamine metabolism manifested by up-regulated polyamine uptake and increased ornithine decarboxylase (ODC) activity."( Role of spermine in amyloid beta-peptide-associated free radical-induced neurotoxicity.
Ain, KB; Butterfield, DA; Varadarajan, S; Yatin, M; Yatin, SM, 2001
)
0.31
" No serious adverse events were reported during the studies, and the only adverse events considered related to treatment were pruritus (three subjects) and dry skin at test site (one subject)."( Human dermal safety studies with eflornithine HCl 13.9% cream (Vaniqa), a novel treatment for excessive facial hair.
Hickman, JG; Huber, F; Palmisano, M, 2001
)
0.59
"2 and experienced significantly fewer cutaneous and neurological adverse effects than did patients who were treated with melarsoprol in 2001 and 2002 (n = 708)."( Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.
Bovier, PA; Chappuis, F; Meussen, A; Stietenroth, K; Udayraj, N, 2005
)
1.77
" Our intention was to retrospectively assess the further incidence of skin cancer, other malignancies, and adverse events of patients accrued to our phase III skin cancer prevention study of DFMO."( A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity.
Bailey, HH; Borich, A; Havighurst, T; Kim, K; Kreul, SM; Mendonça, EA; Snow, S; Verma, A; Wood, GS, 2012
)
0.38
" Safety was further assessed based on treatment emergent adverse events (AEs) occurring during hospitalisation."( In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.
Blesson, S; Blum, J; Ghabri, S; Ilunga, M; Kande, V; Kisala, M; Kuemmerle, A; Lumpungu, I; Mordt, OV; Mubwa, N; Mutanda, S; Mutombo, W; Nganzobo, P; Schmid, C; Tete, D, 2012
)
0.63
" Overall, 155 (75%) of 208 patients had 600 treatment-emergent adverse events."( Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial.
Akwaso Massa, F; Asuka Akongo Nguba, A; Betu Kumeso, VK; Camara, M; Catusse, J; Delhomme, S; Embana Mankiara, H; Fifi Nzeza Bambuwu, A; Ilunga Wa Kyhi, M; Kalonji, WM; Kaninda Badibabi, L; Kasongo Bonama, A; Kavunga Lukula, P; Kobo Muanza, V; Layba Camara, M; Mahenzi Mbembo, H; Makaya Mayawula, J; Mariero Philemon, P; Mokilifi Nganyonyi, R; Mulenge Nasandhel, E; Mutanda Kalonji, S; Mwamba Miaka, E; Ngolo Tete, D; Nusbaumer, M; Prêtre, A; Rembry, S; Scherrer, B; Schneitter, S; Strub-Wourgaft, N; Tarral, A; Valverde Mordt, O, 2023
)
0.91

Pharmacokinetics

Eflornithine was eliminated from plasma with a mean terminal half-life of 11 hours (first application) and 8 hours (final application) Data from three clinical studies were pooled and analyzed using a time-to-event pharmacodynamic modeling approach.

ExcerptReferenceRelevance
" Pharmacokinetic studies demonstrated that the intravenous schedules achieved higher plasma levels of DFMO than those previously obtained with chronic oral dosing."( Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine.
Abeloff, MD; Baylin, SB; Blanc, O; Chien, SC; Griffin, CA; Hermann, J; Luk, GD; Slavik, M; Thompson, G, 1987
)
0.27
"We have determined the pharmacokinetic parameters for diffusion of alpha-[5-14C]-difluoromethylornithine (DFMO) from blood to brain, blood to cerebrospinal fluid (CSF), 9L rat brain tumor to adjacent brain, and blood to the subcutaneously-implanted 9L tumor in rats, and within the CSF of beagle dogs."( Brain, CSF, and tumor pharmacokinetics of alpha-difluoromethylornithine in rats and dogs.
Byrd, DJ; Csejtey, J; Levin, VA, 1983
)
0.27
" DFMO levels were measured using an ion exchange chromatographic assay and pharmacokinetic studies were performed in patients treated at each dose level."( Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.
Abeloff, MD; Baylin, SB; Blanc, O; Griffin, CA; Hermann, J; Luk, GD; Sjoerdsma, A; Slavik, M, 1984
)
0.27
" Eflornithine was eliminated from plasma with a mean terminal half-life of 11 hours (first application) and 8 hours (final application)."( Percutaneous absorption and pharmacokinetics of eflornithine HCl 13.9% cream in women with unwanted facial hair.
Behr, D; Malhotra, B; Noveck, R; Palmisano, M, 2001
)
1.48
"Enantioselective pharmacokinetics and absorption of eflornithine in the rat was investigated using population pharmacokinetic modeling and a modified deconvolution method."( Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat.
Äbelö, A; Artursson, P; Ashton, M; Gennemark, P; Jansson-Löfmark, R; Johansson, CC, 2013
)
0.86
" Data from three clinical studies, (i) eflornithine intravenous monotherapy, (ii) nifurtimox-eflornithine combination therapy, and (iii) eflornithine oral monotherapy, were pooled and analyzed using a time-to-event pharmacodynamic modeling approach, supported by in vitro activity data of the individual enantiomers."( Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy.
Äbelö, A; Amilon, C; Ashton, M; Boberg, M; Jansson-Löfmark, R; Tarning, J, 2022
)
1.26
" We will use DFMO with or without AMXT-1501 to identify candidate pharmacodynamic biomarkers of polyamine depletion in patients with high-grade gliomas in situ ."( Glioma Metabolic Feedback In Situ: A First-In-Human Pharmacodynamic Trial of Difluoromethylornithine + AMXT-1501 Through High-Molecular Weight Microdialysis.
Burns, TC; Hoplin, MD; Kizilbash, SH; Miska, J; Neth, BJ; Riviere-Cazaux, C; Wessel, B, 2023
)
0.91

Compound-Compound Interactions

Eflornithine is safely used in conjunction with laser hair removal treatments and promotes more rapid hair removal when combined with laser treatment. In combination with 2% alpha-difluoromethylornithin (DFMO) in drinking water effected cures of 47/54 mice infected with Plasmodium berghei.

ExcerptReferenceRelevance
"1 mmol/l) was administered in combination with IFN beta (100 and 1000 IU/ml), synergistic antiproliferative activity was observed 7 days after continuous exposure."( Synergistic antiproliferative activity of human fibroblast interferon in combination with alpha-difluoromethylornithine against human gastric cancer cells in vitro.
Kubota, S, 1992
)
0.28
"We have investigated effects of alpha-difluoromethylornithine (DFMO), both as a single agent and in combination with 5-fluorouracil (5-FU) against a human colon tumor xenograft (T6) grown as primary tissue culture in serum-free medium and in combination with doxorubicin (DX) against a human lung adenocarcinoma cell line (A549)."( In vitro response of a human colon tumor xenograft and a lung adenocarcinoma cell line to alpha-difluoromethylornithine alone and in combination with 5-fluorouracil and doxorubicin.
Atabek, U; Zirvi, KA, 1991
)
0.28
" three times per day for 3 days in combination with 2% alpha-difluoromethylornithine (DFMO; eflornithine) in drinking water effected cures of 47/54 mice infected with Plasmodium berghei."( Bis(benzyl)polyamine analogs inhibit the growth of chloroquine-resistant human malaria parasites (Plasmodium falciparum) in vitro and in combination with alpha-difluoromethylornithine cure murine malaria.
Bitonti, AJ; Bush, TL; Dumont, JA; Edwards, ML; McCann, PP; Sjoerdsma, A; Stemerick, DM, 1989
)
0.5
" These data suggest that differentiation agents may provide additional antineoplastic benefits when administered in combination with selected chemotherapeutic agents in the management of prostatic cancer."( Conventional chemotherapeutic agents combined with DMSO or DFMO in treatment of rat prostate carcinoma.
Carvalho, L; Foulkes, K; Mickey, DD, 1989
)
0.28
" When doxorubicin hydrochloride (Adriamycin) was combined with DFMO, synergistic effects were noted at both DFMO concentrations."( Effect of alpha-difluoromethylornithine alone and in combination with doxorubicin hydrochloride, cis-diamminedichloroplatinum (II), and vinblastine sulfate on the growth of P3J cells in vitro.
Allen, ED; Natale, RB, 1986
)
0.27
" Both inhibitors cured the TREU 667 and LUMP 1001 isolates if used in combination with a single (20 mg/kg) injection of suramin, a trypanocide in current clinical use."( Effects of the ornithine decarboxylase inhibitors DL-alpha-difluoromethylornithine and alpha-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models.
Bacchi, CJ; Bienen, EJ; Bitonti, AJ; Clarkson, AB; McCann, PP; Nathan, HC; Sjoerdsma, A, 1987
)
0.27
"alpha-Difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, was administered in combination with human leukocyte interferon to human lymphoblastoid (Daudi) cells in culture."( Synergistic antiproliferative activity of leukocyte interferon in combination with alpha-difluoromethylornithine against human cells in culture.
Gutterman, JU; Rosenblum, MG, 1984
)
0.27
" On the basis of these prior findings, we investigated the effects of alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase, alone and in combination with cis-diamminedichloroplatinum(II) (cisplatin), to which two of the four cell lines display relative resistance."( Inhibition of growth of human or hamster pancreatic cancer cell lines by alpha-difluoromethylornithine alone and combined with cis-diamminedichloroplatinum(II).
Black, O; Chang, BK; Gutman, R, 1984
)
0.27
"The effects of alpha-difluoromethylornithine (DFMO; RMI 71782) in combination with vindesine or Adriamycin were investigated in three different animal tumor models."( Effects of alpha-difluoromethylornithine alone and combined with adriamycin or vindesine on L1210 leukemia in mice, EMT6 solid tumors in mice, and solid tumors induced by injection of hepatoma tissue culture cells in rats.
Bartholeyns, J; Koch-Weser, J, 1981
)
0.26
"The antiproliferative effects of human recombinant interferon gamma (IFN gamma) in combination with alpha-difluoromethylornithine (DFMO) or as single agents were assessed on human cell cultures derived from carcinomas of the breast (MCF-7), the ovary (EFO-27) or the kidneys (EGI-4)."( Antiproliferative effects of interferon gamma in combination with alpha-difluoromethylornithine on human carcinoma cell cultures.
Hölzel, F; Kirchner, H; Klouche, M, 1994
)
0.29
"The toxicity of DFMO in combination with TAM was evaluated in female Beagle dogs following 13 weeks of daily oral administration by capsule."( Thirteen-week oral toxicity study of difluoromethylornithine in combination with tamoxifen citrate in female dogs.
Brown, AP; Crowell, JA; Levine, BS; Morrissey, RL, 1999
)
0.3
"The toxicity of DFMO in combination with TAM was evaluated in female rats following 13 weeks of daily administration by gavage."( Difluoromethylornithine in combination with tamoxifen in female rats: 13-week oral toxicity study.
Brown, AP; Crowell, JA; Levine, BS; Morrissey, RL, 1999
)
0.3
"Effects of polyamine (PA) synthesis inhibitors--alpha-difluoromethylornithinchloride (DFMO) and alpha-methylornithinchloride (MO)--separately or in combination with the epidermal growth factor (EGF)--on lysosome-phagosome fusion (P-LF) and F-actin content in murine peritoneal macrophages were studied using fluorescent dye Acridine orange for lysosome labelling, FITC-phalloidin for F-actin, and yeast cells as a target."( [Effect of polyamine synthesis inhibitors separately and in combination with epidermal growth factor on fusion of lysosomes with phagosomes and F-actin level in mouse peritoneal macrophages].
Beliaeva, TN; Bulychev, AG; Leont'eva, EA; Mozhenok, TP, 2000
)
0.31
" However, drug combination therapies expected to potentiate the effects of these drugs have yet to be systematically pursued."( The role of polyamines in human cancer: prospects for drug combination therapies.
Bachmann, AS, 2004
)
0.32
"Eflornithine is safely used in conjunction with laser hair removal treatments and promotes more rapid hair removal when combined with laser treatment."( Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial.
Beger, B; Littler, C; Piacquadio, DJ; Smith, SR, 2006
)
3.22
"This was a randomized, double-blind, placebo-controlled, right-left comparison study of eflornithine cream combined with laser treatment versus laser alone for treating unwanted hair on the upper lip in women."( A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women.
Hamzavi, I; Lui, H; Shapiro, J; Tan, E, 2007
)
0.81
" This paper discusses the development of a group of lipophilic polyamine analogues that potently inhibit the cellular polyamine uptake system and greatly increase the effectiveness of polyamine depletion when used in combination with DFMO, a well-studied polyamine biosynthesis inhibitor."( Lipophilic lysine-spermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitor.
Burns, MR; Chen, Y; Graminski, GF; O'Brien, TG; Weeks, RS, 2009
)
0.35
" Study results show that P-S/DFMO is an efficacious drug combination for colon cancer prevention and also show the safety of P-S, which may overcome the limiting side effects of conventional sulindac."( Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
Huang, L; Komninou, D; Kopelovich, L; Mackenzie, GG; Ouyang, N; Rigas, B; Sun, Y; Vrankova, K; Xie, G, 2011
)
0.37
" In the present paper we report the synergistic effects of specific oligoamines in combination with DFMO (2-difluoromethylornithine), an inhibitor of ornithine decarboxylase, in human colorectal cancer cells."( Oligoamine analogues in combination with 2-difluoromethylornithine synergistically induce re-expression of aberrantly silenced tumour-suppressor genes.
Casero, RA; Marton, LJ; Murray-Stewart, T; Steinbergs, N; Wu, Y, 2012
)
0.38
" Here, we tested DFMO in combination with a polyamine transport inhibitor (PTI), Trimer44NMe, against Gemcitabine-resistant PDAC cells."( Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
Altomare, DA; Copik, AJ; Gitto, SB; Hogan, FC; Oyer, JL; Pandey, V; Phanstiel, O, 2018
)
0.48

Bioavailability

The techniques are implemented using the optimisation software CasADi. The oral absorption rate and bioavailability of the drug eflornithine are estimated using pharmacokinetic data from rats. Energy intake is estimated from body-mass measurements of mice exposed to monoclonal antibodies targeting the fibroblast growth factor receptor (FGFR) 1c.

ExcerptReferenceRelevance
" Bioavailability of the 10 mg/kg dose was estimated as 58% from the urinary recoveries and as 54% from the areas under the plasma concentration curves (AUC 0 leads to infinity)."( Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase.
Alken, RG; Grove, J; Haegele, KD; Koch-Weser, J; Schechter, PJ, 1981
)
0.26
" A "priming" with difluoromethyl ornithine may therefore offer a means to enhance the epidermal accumulation of otherwise poorly absorbed methylglyoxal bis(guanylhydrazone)."( Effect of epidermal polyamine depletion on the accumulation of methylglyoxal bis(guanylhydrazone) in mouse skin.
Jänne, J; Käpyaho, K; Linnamaa, K, 1982
)
0.26
" In this study, we propose a strategy to enhance the bioavailability of DFMO by using lipidomimetic derivatives."( Studies on lipidomimetic derivatives of alpha-difluoromethylornithine (DFMO) to enhance the bioavailability in a Trypanosoma B. brucei murine trypanosomiasis model.
Bourass, J; Chauffert, O; Czok, M; Letourneux, Y; Loiseau, PM, 1998
)
0.3
"The purpose of this study was to assess the bioavailability of two oral preparations of difluoromethylornithine (DFMO)."( Bioavailability study of oral liquid and tablet forms of alpha-difluoromethylornithine.
Carbone, PP; Douglas, JA; Hamielec, M; Pauk, D; Pomplun, M; Thomas, J; Tutsch, K, 2000
)
0.31
" Bioavailability of an orally administered 10 mg kg(-1) dose was estimated at 54%."( Eflornithine for the treatment of human African trypanosomiasis.
Brun, R; Burri, C, 2003
)
1.76
"A decrease in nitric oxide (NO) bioavailability has been proposed to contribute to endothelial dysfunction and increased peripheral resistances during essential arterial hypertension."( Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats.
Berthelot, A; Demougeot, C; Marie, C; Prigent-Tessier, A, 2005
)
0.33
" Oral bioavailability was estimated by deconvolution at 30 and 59% for L- and D-eflornithine."( Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat.
Äbelö, A; Artursson, P; Ashton, M; Gennemark, P; Jansson-Löfmark, R; Johansson, CC, 2013
)
0.84
"Up-regulation of arginase contributes to airways hyperresponsiveness (AHR) in asthma by reducing L-arginine bioavailability for the nitric oxide (NO) synthase isozymes."( Increased ornithine-derived polyamines cause airway hyperresponsiveness in a mouse model of asthma.
Gauvreau, GM; Grasemann, H; Inman, MD; Khanna, N; North, ML; Scott, JA, 2013
)
0.39
" Our compound optimization that has led to synthesis of several potent 4-anilinoquinazolines, including NEU617, 23a, a highly potent, orally bioavailable inhibitor of trypanosome replication."( Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.
Behera, R; Edwards, P; Guyett, PJ; Karver, CE; Mensa-Wilmot, K; Patel, G; Pollastri, MP; Roncal, NE; Sullenberger, C, 2013
)
0.39
" These techniques are implemented using the optimisation software CasADi, and applied to two example problems: one where the oral absorption rate and bioavailability of the drug eflornithine are estimated using pharmacokinetic data from rats, and one where energy intake is estimated from body-mass measurements of mice exposed to monoclonal antibodies targeting the fibroblast growth factor receptor (FGFR) 1c."( Input estimation for drug discovery using optimal control and Markov chain Monte Carlo approaches.
Ahnmark, A; Chappell, MJ; Evans, ND; Gennemark, P; Lindén, D; Trägårdh, M, 2016
)
0.63
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" However, it has inadequate oral bioavailability and low blood-brain barrier permeation, thus requiring a lengthy and complicated intravenous infusion schedule."( Improving Eflornithine Oral Bioavailability and Brain Uptake by Modulating Intercellular Junctions With an E-cadherin Peptide.
Chen, Y; Feng, M; Rodriguez, L; Wang, MZ; Wu, JQ; Yang, S, 2019
)
0.92

Dosage Studied

Eflornithine stereoselective pharmacokinetics needs to be considered if an oral dosage regimen is to be explored further. The introduction of the combination of nifurtimox and eflornitine (NECT) has accelerated the shift from melarsoprol to the best treatment available.

ExcerptRelevanceReference
" Optimum dosage and duration of therapy, modes of administration and potential for large scale use are discussed."( Advances in sleeping sickness therapy.
Van Nieuwenhove, S, 1992
)
0.28
" ODC gene dosage was analyzed by Southern blot hybridization and was 4- to 12-fold higher in T-47D, MDA-MB-231, and BT-20 cell lines than in the MCF-7 cell line."( Variations in amplification and expression of the ornithine decarboxylase gene in human breast cancer cells.
Jänne, OA; Kiang, DT; Thomas, T; Thomas, TJ, 1991
)
0.28
" In a dexamethasone-resistant cell line that overproduced ODC mRNA at normal gene dosage there were some minor differences between the methylation pattern of the ODC gene of different clones, but no such hypomethylation could be found in clones from the parental cell line."( Certain changes in ornithine decarboxylase gene methylation accompany gene amplification.
Wahlfors, J, 1991
)
0.28
" We have now employed the PCR combined with reverse transcription to determine semiquantitatively ODC gene dosage and the amounts of heterogeneous nuclear (hn) RNA and of mature mRNA of the enzyme in parental and alpha-difluoromethylornithine-resistant human myeloma cells."( Levels of ornithine decarboxylase genomic sequences, heterogeneous nuclear RNA and mRNA in human myeloma cells resistant to alpha-difluoromethylornithine.
Alhonen, L; Halmekytö, M; Hyttinen, IM; Jänne, J, 1991
)
0.28
" All of these drugs were able to induce rapid loss of dhfr gene dosage in the R500 cell population."( Drug-induced loss of unstably amplified genes.
Snapka, RM; Wani, MA, 1990
)
0.28
" A (donor) mouse, infected for 28 days, is dosed with a drug, or combination of drugs, and samples of blood, cerebral cortex, choroid plexus and lining of ventricle are injected into clean (recipient) mice."( Screening compounds for sleeping sickness therapy without relapse.
Ormerod, WE; Raseroka, BH, 1988
)
0.27
" Maternal weight gain was significantly reduced in a dose-response manner, but litter size and pup weight on postnatal day (PND) 1 were unaffected."( Effect of prenatal imipramine exposure on development of the postnatal rat heart and brain.
Delongchamp, RR; Harmon, JR; Kimmel, GL; Webb, PJ, 1986
)
0.27
" The overproduction of ornithine decarboxylase by the tumor cells grown under the pressure of difluoromethylornithine was at least partly attributable to a 10 to 20-fold increase in the total gene dosage of ornithine decarboxylase involving an amplification of several genes of the gene family."( Difluoromethylornithine-induced amplification of ornithine decarboxylase genes in Ehrlich ascites carcinoma cells.
Alhonen-Hongisto, L; Jänne, J; Jänne, OA; Kallio, A; Kontula, KK; Seppänen, P; Sinervirta, R, 1985
)
0.27
" Median effect analysis of the DFMO + IFN inhibition of C8161 cells demonstrated that the 2 agents interacted synergistically over the entire dose-response curve."( Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone A interferon and retinoic acid.
Bregman, MD; Meyskens, FL, 1986
)
0.27
" Plating efficiency assays were used to generate ADR dose-response survival curves for DFMO-treated and control cultures."( Reduced cytocidal efficacy for adriamycin in cultured human carcinoma cells depleted of polyamines by difluoromethylornithine treatment.
Block, AL; Komar, KA; Naujokas, MF; Seidenfeld, J, 1986
)
0.27
" Five patients are described with Gambian trypanosomiasis treated in Belgium with difluoromethylornithine, using various intravenous and oral dosage schedules."( Difluoromethylornithine, an effective new treatment of Gambian trypanosomiasis. Results in five patients.
Dasnoy, J; Haegele, KD; Kazyumba, G; Marcelis, L; Schechter, PJ; Sjoerdsma, A; Sonnet, J; Taelman, H; Wery, M, 1987
)
0.27
" These changes closely paralleled the temporal and dose-response characteristics of changes in total lung DNA synthesis."( DNA synthesis in pulmonary alveolar macrophages and type II cells: effects of ozone exposure and treatment with alpha-difluoromethylornithine.
Brady, AN; D'Arcy, JB; Li, LC; Smiler, KL; White, DM; Wright, ES, 1987
)
0.27
" Restriction enzyme analyses of genomic DNA isolated from the resistant cells indicated that the gene dosage for ornithine decarboxylase was not increased to any appreciable extent."( Human myeloma cells acquire resistance to difluoromethylornithine without overproducing ornithine decarboxylase.
Alhonen-Hongisto, L; Jänne, J; Laine, R; Leinonen, P, 1987
)
0.27
" These cells, now grown for more than 2 years in the presence of DFMO and cadaverine, continued to accumulate ODC-specific mRNA in an amount 30-50 times higher than that in the parental cells, yet showing practically no changes in the gene dosage for the enzyme."( Cadaverine supplementation during a chronic exposure to difluoromethylornithine allows an overexpression, but prevents gene amplification, of ornithine decarboxylase in L1210 mouse leukaemia cells.
Alhonen-Hongisto, L; Hirvonen, A; Jänne, J; Sinervirta, R, 1987
)
0.27
" When lower levels of shock, which caused no loss of consciousness, were also used, a clear dose-response relationship of shock intensity and ornithine decarboxylase activity was found for hippocampus and brain stem."( Regional variation in the response of cerebral ornithine decarboxylase to electroconvulsive shock.
Bondy, SC; Mason, G; Mitchell, CL; Rahmaan, S, 1987
)
0.27
" Intravenous TMP-SMX was begun at a dosage of 18 mg/kg/day of trimethoprim."( Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
Hauptman, SP; Wordell, CJ, 1988
)
0.27
" The higher dosage (0."( Preventive treatment of rabbit coccidiosis with alpha-difluoromethylornithine.
Alunda, JM; Ordóñez-Escudero, D; San Martín-Núñez, BV, 1988
)
0.27
" Plating efficiency assays were used to generate BCNU dose-response survival curves for DFMO-treated and control cells."( Chemosensitization of cultured human carcinoma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea by difluoromethylornithine-induced polyamine depletion.
Komar, KA; Seidenfeld, J, 1985
)
0.27
" A dose-response curve was developed for each interferon in which the maximum dose applied gave at least 30% growth inhibition of control values after 96-128 h of continuous exposure."( The in vitro interaction of alpha-difluoromethyl ornithine (DFMO) and several interferons on human cell lines.
Harvey, HA; Leitzel, KE; Lipton, A; Pegg, AE; Wolf, LM, 1985
)
0.27
" One group, termed stuporous (AS), received only enough ammonium acetate to interfere with grooming and exploratory activity; this dosage was insufficient to completely block the righting response, which was absent in the AC group."( Disruption of the blood-brain barrier in hyperammonemic coma and the pharmacologic effects of dexamethasone and difluoromethyl ornithine.
Chandler, MD; McCandless, DW; Sears, ES, 1985
)
0.27
" In addition, a simplified, once daily dosage of DFMO appears adequate."( Inhibition of ornithine decarboxylase activity by small doses of alpha-difluoromethylornithine.
Loprinzi, CL; Verma, AK, 1985
)
0.27
" Vomiting, necessitating dosage reduction, was a significant problem at the highest dose administered."( Phase I evaluation of intravenous difluoromethylornithine--a polyamine inhibitor.
Estey, E; Freireich, EJ; Keating, MJ; Maddox, AM; McCredie, KE, 1985
)
0.27
" Dose-response studies with MGBG (0 to 30 microM for 40 to 48 hr) revealed that, of the parameters related to polyamine metabolism (i."( Biochemical and ultrastructural characterization of human cell variants resistant to the antiproliferative effects of methylglyoxal bis(guanylhydrazone).
Kramer, DL; Porter, CW; Wiseman, A; Zychlinski, L, 1983
)
0.27
" As a result of treatment with the highest intravenous dosage (1000 mg/kg/day), villous atrophy of the mucosa was observed by light and scanning electron microscopy in the canine small intestine."( Intestinal changes caused by DL-alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase.
Diekema, KA; Gibson, JP; Loudy, DE; McCann, PP; Sprinkle, DJ; Yarrington, JT, 1983
)
0.27
" Dosage of CSF polyamines was proved to be useful in monitoring patients with medulloblastomas and others malignancies with meningeal involvement."( Polyamines: current review and their perspectives in neurosurgery.
Occhiogrosso, M; Pierangeli, E; Vailati, G,
)
0.13
" Both marked antitumor effects and side effects were observed in mice treated at the dosage of DFMO 500 mg/kg/day and/or MGBG 50 mg/kg/day and/or MGBG 30 mg/kg/day brought about significant antitumor effects as well as less side effects."( [Antitumor effects of polyamine synthesis inhibitors based on major premise of treatment for human malignant tumor].
Fujimoto, S; Hirose, S; Igarashi, K; Okui, K; Shrestha, RD; Terao, K, 1982
)
0.26
" Although the three sublines were 2- to 10-fold less sensitive than the parent line to classical MDR-type agents, they were found in dose-response studies to be significantly more sensitive to DENSPM than the parent line."( Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine.
Bergeron, RJ; Ganis, B; Kramer, DL; Porter, CW; Rustum, Y; Wrzosek, C, 1994
)
0.29
" Furthermore, the extent and direction of the modulation of ricin toxicity is highly dependent upon pharmacokinetic variables, including dose and dosing interval."( Modulation of ricin toxicity in mice by biologically active substances.
Muldoon, DF; Stohs, SJ,
)
0.13
" Oltipraz was fed in the diet from one week prior to OH-BBN dosing until sacrifice, six months later."( Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO.
Detrisac, CJ; Kelloff, GJ; Moon, RC; Sigman, CC; Steele, VE; Thomas, CF,
)
0.13
" To avoid treatment failures, a 6-hourly regimen as well as higher DFMO dosage based on body surface area rather than on weight are recommended for children."( Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness.
Ethier, L; Loko, L; Milord, F; Mpia, B; Pépin, J,
)
1.57
" DFMO has shown a dose-response effect in tumor inhibition in mice."( Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine.
Carbone, PP; Carey, P; Gilmore, D; Love, RR; Pomplun, M; Tutsch, KD; Verma, AK; Wilding, G, 1993
)
0.29
" Initially dose-response and time-course studies of [3H]putrescine uptake were performed."( Uptake of extracellular, dietary putrescine is an important regulatory mechanism of intracellular polyamine metabolism during camostate-induced pancreatic growth in rats.
Fölsch, UR; Löser, C; Torff, L, 1997
)
0.3
"The dose-response relationship in male F344 rats was determined for the ability of aspirin administered in the diet to prevent azoxymethane (AOM)-induced colon cancer and aberrant crypt foci (ACF) and to reduce prostaglandin E2 (PGE2) levels."( Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon.
Conran, P; Hawk, EE; Kelloff, GJ; Kramer, PM; Li, H; Lubet, RA; Pereira, MA; Schut, HA; Steele, VE, 1999
)
0.3
"4%) inflammatory reactions on their DFMO-treated arms which required dosing modification."( Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine.
Aickin, M; Alberts, DS; Bowden, GT; Dorr, RT; Einspahr, JG; Foote, JA; Goldman, R; Peng, YM; Roe, DJ; Saboda, K; Salasche, S; Warneke, JA; Xu, MJ, 2000
)
0.31
" The objectives of these three experiments were to: 1) determine a dose and dosing schedule of DFMO that produces significant hearing loss (HL) in newborn gerbils; 2) compare the HL level for control and newborn gerbils receiving daily subcutaneous injections of DFMO; and 3) to determine if DFMO-related HL is significantly reversible following discontinuation of DFMO treatment."( Delayed, reversible hearing loss caused by difluoromethylornithine (DFMO).
Doyle, KJ, 2001
)
0.31
"50 ng/ml) after 4 days of twice-daily topical treatment, and multiple dosing had no apparent effect on disposition kinetics."( Percutaneous absorption and pharmacokinetics of eflornithine HCl 13.9% cream in women with unwanted facial hair.
Behr, D; Malhotra, B; Noveck, R; Palmisano, M, 2001
)
0.57
" However, a dose-response reduction in invasive carcinoma growth was observed for both DFMO, an inhibitor of ornithine decarboxylase, and DHEA, the primary steroid precursor to both androgens and estrogens in primates."( 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Anver, MR; Green, JE; Kelloff, G; Lubet, R; Moon, RC; Shibata, E; Shibata, MA, 2001
)
0.31
" We found that DFMO administration to MCF-10A cells increased EGF-R mRNA and protein levels in a dose-response fashion, while HER-2neu expression was not affected."( Effect of alpha-difluoromethyl-ornithine on the expression and function of the epidermal growth factor receptor in human breast epithelial cells in culture.
Demers, L; Manni, A; Mauger, D; Trout, D; Verderame, MF; Washington, S, 2001
)
0.31
" Previous neonatal gerbil studies have identified a dosing regimen of 1 g/kg per day of DFMO given for 3 weeks that results in reversible HL on click-evoked auditory brainstem response (ABR)."( Difluoromethylornithine-induced reversible hearing loss across a wide frequency range.
Doyle, KJ; Smith, MC; Tinling, S, 2004
)
0.32
" Treatment of cells with a second inhibitor of polyamine biosynthesis, the S-adenosylmethionine decarboxylase (SAMDC) inhibitor SAM486A, also resulted in a dosage dependent decrease in meprin alpha and MMP-7 mRNA."( Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin alpha and MMP-7 in hormone-independent human breast cancer cells.
Bond, JS; Manni, A; Matters, GL, 2005
)
0.33
" A combination chemotherapy, eflornithine alongside nifurtimox, has been introduced to decrease the time frame and overall dosing of eflornithine and reducing the risk of drug resistance emerging."( Potential new drugs for human African trypanosomiasis: some progress at last.
Barrett, MP, 2010
)
0.65
" If increased plasma concentrations of eflornithine could be achieved in this way, an oral dosage form would be possible."( Mono-, di- and trisubstituted derivatives of eflornithine: synthesis for in vivo delivery of DL-alpha-difluoromethylornithine in plasma.
Ashton, M; Breytenbach, JC; Cloete, TT; Johansson, CC; N'Da, DD; Rottenberg, ME; Vodnala, SK, 2011
)
0.9
" However, a need for protracted and complicated drug dosing regimens slowed widespread implementation of eflornithine monotherapy."( Drug resistance in human African trypanosomiasis.
Barrett, MP; Burchmore, RJ; Kazibwe, AJ; Matovu, E; Vincent, IM, 2011
)
0.58
" The introduction of the combination of nifurtimox and eflornithine (NECT) has accelerated the shift from melarsoprol to the best treatment available, due to reduced dosage and treatment time for eflornithine that has significantly lessened the cost and improved the burden of logistics encountered during treatment and distribution."( Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis.
Diarra, A; Franco, J; Jannin, J; Postigo, JA; Simarro, PP, 2012
)
0.63
" Eflornithine stereoselective pharmacokinetics needs to be considered if an oral dosage regimen is to be explored further."( Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.
Ashton, M; Björkman, S; Doua, F; Jansson-Löfmark, R; Na-Bangchang, K, 2015
)
1.55
" Increasing the dosage of the immunotherapeutic increased the magnitude (intensity and duration) of the pain behavior."( Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO.
Diccianni, MB; Gangoti, JA; Kempińska, K; Sorkin, LS; Yu, AL, 2020
)
0.56
"α-Difluoromethylornithine or Eflornithine is an FDA-approved drug used for the treatment of Sleeping Sickness (as vials dosage form) and also used for diminishing the unwanted excess facial hair in the hirsutism (as creams dosage form)."( Micellar sensitized Resonance Rayleigh Scattering and spectrofluorometric methods based on isoindole formation for determination of Eflornithine in cream and biological samples.
Abdel-Lateef, MA; Almahri, A, 2021
)
1.12
" One key challenge of DFMO is its rapid renal clearance and the need for high and frequent drug dosing during treatment."( Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.
Bachmann, AS; Dowling, TC; Schultz, CR; Swanson, MA, 2021
)
0.62
" Standard dosing of eflornithine consists of repeated intravenous infusions of a racemic mixture of L- and D-eflornithine."( Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy.
Äbelö, A; Amilon, C; Ashton, M; Boberg, M; Jansson-Löfmark, R; Tarning, J, 2022
)
1.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
trypanocidal drugA drug used to treat or prevent infections caused by protozoal organisms belonging to the suborder Trypanosomatida.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
fluoroamino acidAn organofluorine compound that consists of an amino acid substituted by a fluoro group.
alpha-amino acidAn amino acid in which the amino group is located on the carbon atom at the position alpha to the carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency6.70160.531815.435837.6858AID504845
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency7.07950.035520.977089.1251AID504332
chromobox protein homolog 1Homo sapiens (human)Potency63.09570.006026.168889.1251AID488953
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ornithine decarboxylaseRattus norvegicus (Norway rat)Ki39.00002.70002.70002.7000AID150884
60 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)175.00000.17004.559010.0000AID1320592; AID1320594
10 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)175.00000.17004.559010.0000AID1320592; AID1320594
60 kDa chaperonin Escherichia coliIC50 (µMol)175.00000.03903.55529.8000AID1320591; AID1320593
10 kDa chaperonin Escherichia coliIC50 (µMol)175.00000.03903.55529.8000AID1320591; AID1320593
Mitochondrial 2-oxodicarboxylate carrierHomo sapiens (human)IC50 (µMol)252.00000.01100.01100.0110AID1675137
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
adhesion of symbiont to host60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell mediated immune response to tumor cell60 kDa heat shock protein, mitochondrialHomo sapiens (human)
'de novo' protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to cold60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interferon-alpha production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-10 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-12 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-6 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein refolding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell proliferation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of macrophage activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
negative regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isotype switching to IgG isotypes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein stabilization60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone-mediated protein complex assembly60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein maturation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
biological process involved in interaction with symbiont60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cellular response to interleukin-760 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein import into mitochondrial intermembrane space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial unfolded protein response60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apoptotic mitochondrial changes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
osteoblast differentiation10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process10 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein10 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone cofactor-dependent protein refolding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
lysine catabolic processMitochondrial 2-oxodicarboxylate carrierHomo sapiens (human)
lipid transportMitochondrial 2-oxodicarboxylate carrierHomo sapiens (human)
mitochondrial alpha-ketoglutarate transmembrane transportMitochondrial 2-oxodicarboxylate carrierHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
lipopolysaccharide binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
p53 binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
DNA replication origin binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
single-stranded DNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
double-stranded RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
high-density lipoprotein particle binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isomerase activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP hydrolysis activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
enzyme binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ubiquitin protein ligase binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein A-I binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP-dependent protein folding chaperone60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding chaperone10 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
metal ion binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
alpha-ketoglutarate transmembrane transporter activityMitochondrial 2-oxodicarboxylate carrierHomo sapiens (human)
antiporter activityMitochondrial 2-oxodicarboxylate carrierHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytoplasm60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrion60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
early endosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytosol60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
clathrin-coated pit60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cell surface60 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
coated vesicle60 kDa heat shock protein, mitochondrialHomo sapiens (human)
secretory granule60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm midpiece60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
migrasome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-containing complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
lipopolysaccharide receptor complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrion10 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome10 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix10 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membraneMitochondrial 2-oxodicarboxylate carrierHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (206)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID482889Inhibition of human liver cathepsin B2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID780226Inhibition of ornithine decarboxylase in Trypanosoma brucei rhodesiense STIB900 assessed as intracellular ornithine level at 50 uM after 20 mins (Rvb = 4 +/- 1 uM)2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Cynaropicrin targets the trypanothione redox system in Trypanosoma brucei.
AID412664Selectivity index ratio IC50 for human MRC5 cells to IC50 for Trypanosoma brucei brucei GUTat3.12008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
New lycorine-type alkaloid from Lycoris traubii and evaluation of antitrypanosomal and antimalarial activities of lycorine derivatives.
AID530084Tmax in Sprague-Dawley rat at 750 to 3000 mg/kg, po2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Enantioselective and nonlinear intestinal absorption of eflornithine in the rat.
AID1740561Selectivity index, ratio of CC50 for human HepG2 cells to EC50 for Trypanosoma brucei brucei AnTat 1.92020European journal of medicinal chemistry, Sep-15, Volume: 2028-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi.
AID1320595Cytotoxicity against human THLE3 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
AID40886The compound was tested on [3H]spermidine uptake into BL6 cells at 0.0(mM)conc1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID40890The compound was tested on [3H]-spermidine uptake into BL6 cells at 0.75(mM)conc1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID1064495Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for Trypanosoma brucei brucei GUTat 3.12014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Semisynthesis of salviandulin E analogues and their antitrypanosomal activity.
AID530088Peripheral volume of distribution in Sprague-Dawley rat assessed as D-eflornithine at 375 mg/kg, iv administered as single infusion2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Enantioselective and nonlinear intestinal absorption of eflornithine in the rat.
AID1480082Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB 900 assessed as parasite growth inhibition after 72 hrs by Alamar blue assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID482887Antitrypanosomal activity against Trypanosoma brucei brucei2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID40884The compound was tested on spermidine content of the cells at 0.75(mM)conc1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID482885Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain at 100 uM2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1548448Selectivity index, ratio of CC50 for human HepG2 cells to EC50 for Trypanosoma brucei brucei trypomastigotes AnTat 1.9
AID1675140Antiproliferative activity against human SK-N-BE(2)-M17 cells after 24 hrs
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID694135Inhibition of protein synthesis in Trypanosoma brucei assessed as reduction in [3H]L-histidine incorporation into proteins incubated for 4 hrs by scintillation counting2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization.
AID530086Intercompartmental clearance in Sprague-Dawley rat assessed as L-eflornithine at 1000 mg/kg, iv administered as 3 mins short-term infusion2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Enantioselective and nonlinear intestinal absorption of eflornithine in the rat.
AID548280Antimicrobial activity against Trypanosoma brucei2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1064497Antitrypanosomal activity against Trypanosoma brucei brucei GUTat 3.1 after 72 hrs by AlamarBlue assay2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Semisynthesis of salviandulin E analogues and their antitrypanosomal activity.
AID1675139Antiproliferative activity against human SK-N-AS cells after 24 hrs
AID1503252Cytotoxicity against human THP1 cells
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1548447Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID473011Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain by standard fluorescence assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID530083Mean transit time in Sprague-Dawley rat assessed as L-eflornithine at 750 to 3000 mg/kg, po2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Enantioselective and nonlinear intestinal absorption of eflornithine in the rat.
AID700325Antitrypanosomal activity against wild type Trypanosoma brucei bloodstream form assessed as growth inhibition after 3 days by Alamar blue assay2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Design, synthesis, and evaluation of potential prodrugs of DFMO for reductive activation.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1503251Antitrypanosomal activity against trypomastigote form of Trypanosoma brucei after 72 hrs by Alamar blue assay
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1675138Antiproliferative activity against human SK-N-FI cells after 24 hrs
AID530089Peripheral volume of distribution in Sprague-Dawley rat assessed as L-eflornithine at 375 mg/kg, iv administered as single infusion2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Enantioselective and nonlinear intestinal absorption of eflornithine in the rat.
AID40885The compound was tested on spermidine content of the cells at 1.0(mM)conc1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID23589Pharmacokinetic parameter half life was determined at a concentration of 10 uM1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
alpha-(Fluoromethyl)dehydroornithine and alpha-(fluoromethyl)dehydroputrescine analogues as irreversible inhibitors of ornithine decarboxylase.
AID473009Inhibition of Plasmodium falciparum recombinant falcipain-2 using Cbz-Leu-Arg-AMC as substrate by standard fluorescence assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID548284Selectivity ratio of EC50 for Trypanosoma brucei NfxR2 to EC50 for Trypanosoma brucei2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1503250Antileishmanial activity against amastigote form of Leishmania donovani infected in human THP1 cells after 72 hrs by Alamar blue assay
AID279019Growth inhibition of J774A.1 macrophage cells after 24 hrs by MTT method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID1503248Antileishmanial activity against promastigote form of Leishmania donovani after 72 hrs by Alamar blue assay
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1503249Antileishmanial activity against anexin amastigote form of Leishmania donovani after 72 hrs by Alamar blue assay
AID700326Activity of His-tagged Trypanosoma brucei nitroreductase assessed as oxidation of NADH2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Design, synthesis, and evaluation of potential prodrugs of DFMO for reductive activation.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID482888Inhibition of human liver cathepsin B at 100 uM2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID150884The apparent dissociation constant for irreversible inhibition of rat liver ornithine decarboxylase (ODC)1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
alpha-(Fluoromethyl)dehydroornithine and alpha-(fluoromethyl)dehydroputrescine analogues as irreversible inhibitors of ornithine decarboxylase.
AID1320591Inhibition of Escherichia coli GroEL/GroES expressed in Escherichia coli DH5alpha/BL21 (DE3) assessed as inhibition of denatured MDH refolding preincubated for 10 mins followed by ATP addition measured after 20 to 40 mins by fluorescence based assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
AID494011Inhibition of hair growth in C3H/HeN mouse model assessed as inhibition of hair growth after 14 days2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Smoothened antagonists for hair inhibition.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1181720Antimicrobial activity against promastigote stage of Leishmania donovani after 72 hrs by Alamar Blue assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis, antileishmanial and antitrypanosomal activities of N-substituted tetrahydro-β-carbolines.
AID1896766Decrease in intracellular polyamine level in human L3.6pl cells assessed as putrescine level at 60 uM incubated for 24 hrs by HPLC analysis
AID736304Antiparasitic activity against Trypanosoma brucei assessed as growth inhibition2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Examination of the mode of action of the almiramide family of natural products against the kinetoplastid parasite Trypanosoma brucei.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1320594Inhibition of human mitochondrial HSP60/HSP10-ATPase activity expressed in Escherichia coli DH5alpha/BL21 (DE3) assessed as inhibition of denatured MDH refolding preincubated for 10 mins followed by ATP addition measured after 40 to 60 mins by malachite g2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
AID1320597Inhibition of pig heart native MDH reporter reaction after 20 to 40 mins by fluorescence based assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
AID40755The compound was tested in vitro for inhibition of cell growth on the B16-BL6 melanoma cells at 0.75(mM)conc.1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID40889The compound was tested on [3H]spermidine uptake into BL6 cells at 0.5(mM)conc1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID285447Anticryptosporidial activity against Cryptosporidium parvum infected TCR alpha deficient-mouse assessed as prevention of oocyst shedding at 20 mg/kg/day after 7 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Activities of DL-alpha-difluoromethylarginine and polyamine analogues against Cryptosporidium parvum infection in a T-cell receptor alpha-deficient mouse model.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID40880The compound was tested on spermidine content of the cells at 0.0(mM)conc1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID490974Antitrypanosomal activity against Trypanosoma brucei brucei TC 221 after 24 hrs by alamar blue assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain.
AID1675137Inhibition of ODC (unknown origin) expressed in Escherichia coli after 30 mins in presence of [1-14C] L-ornithine by liquid scintillation counter analysis
AID40891The compound was tested on [3H]spermidine uptake into BL6 cells at 1.0(mM)conc1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID482884Inhibition of Trypanosoma brucei rhodesiense rhodesain after 12 hrs by fluorescence spectroscopy-based on-bead assay2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID279018Growth inhibition of wild type Leishmania donovani AG83 amastigotes in J774A.1 after 5 days by MTT method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID548282Antimicrobial activity against Trypanosoma brucei NfxR22010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1320593Inhibition of Escherichia coli GroEL/GroES-ATPase activity expressed in Escherichia coli DH5alpha/BL21 (DE3) assessed as inhibition of denatured MDH refolding preincubated for 10 mins followed by ATP addition measured after 20 to 40 mins by malachite gree2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
AID418496Antitumor activity against 7,12-dimethylbenz(alpha)anthracene-induced squamous cell carcinoma in FVB/N transgenic mouse model expressing K6/ODC gene assessed as tumor growth inhibition after 4 weeks2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Lipophilic lysine-spermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitor.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID22942The times of half-inactivation constant (T50) was determined for ODC1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
alpha-(Fluoromethyl)dehydroornithine and alpha-(fluoromethyl)dehydroputrescine analogues as irreversible inhibitors of ornithine decarboxylase.
AID40751The compound was tested in vitro for inhibition of cell growth on the B16-BL6 melanoma cells at 0.0(mM)conc.1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID1181721Antimicrobial activity against axenic amastigote stage of Leishmania donovani after 72 hrs by Alamar Blue assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis, antileishmanial and antitrypanosomal activities of N-substituted tetrahydro-β-carbolines.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID40756The compound was tested in vitro for inhibition of cell growth on the B16-BL6 melanoma cells at 1.0(mM)conc.1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID1740560Antileishmanial activity against Trypanosoma brucei brucei AnTat 1.9 measured after 74 hrs by Alamar blue assay2020European journal of medicinal chemistry, Sep-15, Volume: 2028-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi.
AID692981Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900 bloodstream forms assessed as reduction in cell viability after 70 hrs by alamar blue assay2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.
AID692982Cytotoxicity against in rat L6 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.
AID1742372Selectivity index, ratio of CC50 for human HepG2 cells to EC50 for Trypanosoma brucei brucei trypomastigotes AnTat 1.9
AID530090Intercompartmental clearance in Sprague-Dawley rat assessed as D-eflornithine at 375 mg/kg, iv administered as single infusion2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Enantioselective and nonlinear intestinal absorption of eflornithine in the rat.
AID1181722Antimicrobial activity against promastigote stage of Leishmania donovani infected in human THP1 cells after 72 hrs by Alamar Blue assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis, antileishmanial and antitrypanosomal activities of N-substituted tetrahydro-β-carbolines.
AID1317209Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei S16 assessed as inhibition of proliferation measured after 72 hrs by alamarBlue assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Tyrosol and hydroxytyrosol derivatives as antitrypanosomal and antileishmanial agents.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID548283Selectivity ratio of EC50 for Trypanosoma brucei NfxR1 to EC50 for Trypanosoma brucei2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1896767Decrease in intracellular polyamine level in human L3.6pl cells assessed as spermidine level at 60 uM incubated for 24 hrs by HPLC analysis
AID1181723Antimicrobial activity against trypamastigote stage of Trypanosoma brucei after 72 hrs by Alamar Blue assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis, antileishmanial and antitrypanosomal activities of N-substituted tetrahydro-β-carbolines.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID412485Cytotoxicity against human MRC5 cells after 7 days by MTT assay2008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
New lycorine-type alkaloid from Lycoris traubii and evaluation of antitrypanosomal and antimalarial activities of lycorine derivatives.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID40883The compound was tested on spermidine content of the cells at 0.5 mM) conc1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID530096Oral bioavailability in Sprague-Dawley rat at 750 mg/kg, po2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Enantioselective and nonlinear intestinal absorption of eflornithine in the rat.
AID739090Antitrypanosomal activity against bloodstream form Trypanosoma brucei brucei Lister 427 after 48 hrs by hemocytometer2013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.
AID1320592Inhibition of human mitochondrial HSP60/HSP10 expressed in Escherichia coli DH5alpha/BL21 (DE3) assessed as inhibition of denatured MDH refolding preincubated for 10 mins followed by ATP addition measured after 40 to 60 mins by fluorescence based assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
AID1064496Cytotoxicity against human MRC5 cells2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Semisynthesis of salviandulin E analogues and their antitrypanosomal activity.
AID548281Antimicrobial activity against Trypanosoma brucei NfxR12010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1742371Antitrypanosomal activity against bloodstream form Trypanosoma brucei brucei AnTat 1.9 trypomastigotes assessed as reduction in parasite viability incubated for 69 hrs by Alamar Blue dye based assay
AID1320590Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 VSG 221 [TetR T7RNAP] transgenic bloodstream forms assessed as reduction in cell viability after 48 hrs by alamar blue assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
AID1548446Antitrypanosomal activity against Trypanosoma brucei brucei AnTat 1.9 trypomastigotes assessed as reduction in parasite viability incubated for 69 hrs by Alamar Blue dye based assay
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID530082Peripheral volume of distribution in Sprague-Dawley rat assessed as D-eflornithine at 1000 mg/kg, iv administered as 3 mins short-term infusion2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Enantioselective and nonlinear intestinal absorption of eflornithine in the rat.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID40881The compound was tested on spermidine content of the cells at 0.1(mM)conc1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID312529Antitrypanosomal activity against Trypanosoma brucei brucei TC2212008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
In search of novel agents for therapy of tropical diseases and human immunodeficiency virus.
AID1742366Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID473012Antiplasmodial activity against Plasmodium falciparum W2 by flow cytometry2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID530085Peripheral volume of distribution in Sprague-Dawley rat assessed as L-eflornithine at 1000 mg/kg, iv administered as 3 mins short-term infusion2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Enantioselective and nonlinear intestinal absorption of eflornithine in the rat.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1320596Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
AID40752The compound was tested in vitro for inhibition of cell growth on the B16-BL6 melanoma cells at 0.1(mM)conc.1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID530097Oral bioavailability in Sprague-Dawley rat at 1500 mg/kg, po2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Enantioselective and nonlinear intestinal absorption of eflornithine in the rat.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID279017Growth inhibition of wild type Leishmania donovani AG83 promastigotes in J774A.1 cells after 72 hrs by MTT method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID40887The compound was tested on [3H]-spermidine uptake into BL6 cells at 0.1(mM)conc1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID40754The compound was tested in vitro for inhibition of cell growth on the B16-BL6 melanoma cells at 0.5(mM)conc.1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID40882The compound was tested on spermidine content of the cells at 0.25(mM)conc1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID530091Intercompartmental clearance in Sprague-Dawley rat assessed as L-eflornithine at 375 mg/kg, iv administered as single infusion2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Enantioselective and nonlinear intestinal absorption of eflornithine in the rat.
AID482886Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID530099Oral bioavailability in Sprague-Dawley rat at 3000 mg/kg, po2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Enantioselective and nonlinear intestinal absorption of eflornithine in the rat.
AID530098Oral bioavailability in Sprague-Dawley rat at 2000 mg/kg, po2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Enantioselective and nonlinear intestinal absorption of eflornithine in the rat.
AID40753The compound was tested in vitro for inhibition of cell growth on the B16-BL6 melanoma cells at 0.25(mM)conc.1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID412484Antitrypanosomal activity against Trypanosoma brucei brucei GUTat3.1 after 72 hrs by alamar blue assay2008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
New lycorine-type alkaloid from Lycoris traubii and evaluation of antitrypanosomal and antimalarial activities of lycorine derivatives.
AID40888The compound was tested on [3H]spermidine uptake into BL6 cells at 0.25(mM)conc1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID530100Intercompartmental clearance in Sprague-Dawley rat assessed as D-eflornithine at 1000 mg/kg, iv administered as 3 mins short-term infusion2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Enantioselective and nonlinear intestinal absorption of eflornithine in the rat.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID473010Inhibition of Plasmodium falciparum recombinant falcipain-3 by standard fluorescence assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1740557Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay2020European journal of medicinal chemistry, Sep-15, Volume: 2028-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi.
AID530095Mean transit time in Sprague-Dawley rat assessed as D-eflornithine at 750 to 3000 mg/kg, po2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Enantioselective and nonlinear intestinal absorption of eflornithine in the rat.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1345225Human Ornithine decarboxylase (Decarboxylases)2003The Biochemical journal, Oct-15, Volume: 375, Issue:Pt 2
Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,255)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990833 (36.94)18.7374
1990's708 (31.40)18.2507
2000's401 (17.78)29.6817
2010's242 (10.73)24.3611
2020's71 (3.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.69 (24.57)
Research Supply Index7.81 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index137.46 (26.88)
Search Engine Supply Index3.39 (0.95)

This Compound (47.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials93 (3.91%)5.53%
Reviews164 (6.90%)6.00%
Case Studies46 (1.94%)4.05%
Observational0 (0.00%)0.25%
Other2,074 (87.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (45)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Preventative Trial of DFMO (Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in Remission [NCT02395666]Phase 2140 participants (Actual)Interventional2015-03-05Completed
Phase IIB Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine and Topical Diclofenac in the Treatment of Sun-Damaged Skin on the Forearm [NCT00601640]Phase 2184 participants (Actual)Interventional2007-01-31Completed
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan for Patients With Relapsed or Refractory Neuroblastoma [NCT02030964]Phase 130 participants (Anticipated)Interventional2013-12-31Active, not recruiting
A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy [NCT02796261]Phase 3343 participants (Actual)Interventional2016-07-31Active, not recruiting
A Two-Arm Phase II Chemoprevention Trial in Adenomatous Polyposis Coli Patients [NCT00033371]Phase 2205 participants (Actual)Interventional2001-12-13Completed
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer [NCT05500508]Phase 1/Phase 256 participants (Anticipated)Interventional2022-11-29Recruiting
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma [NCT04696029]Phase 2118 participants (Anticipated)Interventional2021-03-29Recruiting
Targeted Chemoprevention of Gastric Carcinogenesis in High Risk Populations [NCT02794428]Phase 291 participants (Actual)Interventional2016-09-19Active, not recruiting
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO) [NCT02679144]Phase 2258 participants (Anticipated)Interventional2016-02-29Recruiting
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma [NCT02559778]Phase 2500 participants (Anticipated)Interventional2015-09-30Recruiting
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma [NCT04301843]Phase 2131 participants (Anticipated)Interventional2020-09-25Recruiting
An Intermediate Expanded Use Trial of DFMO [NCT03581240]0 participants Expanded AccessAvailable
A Phase I/II Trial of DFMO in Combination With Bortezomib in Patients With Relapsed or Refractory Neuroblastoma [NCT02139397]Phase 1/Phase 216 participants (Actual)Interventional2014-05-31Active, not recruiting
A Phase I Trial for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide [NCT01059071]Phase 121 participants (Actual)Interventional2010-02-28Completed
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma [NCT03794349]Phase 295 participants (Anticipated)Interventional2019-07-08Recruiting
Targeting Polyamines Using DFMO in Persons With Type 1 Diabetes: A Randomized, Double-Masked, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, and Initial Pharmacodynamics of Multiple Ascending Doses [NCT02384889]Phase 141 participants (Actual)Interventional2015-04-30Completed
Repeat Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Asymptomatic Patients With Metastatic Castration-Resistant Prostate Cancer: The APEX (Androgen and Polyamine Elimination Alternating With Xtandi) Trial [NCT06059118]Phase 250 participants (Anticipated)Interventional2023-10-04Recruiting
An Open-label, Phase 1b Study to Evaluate the Safety and Tolerability of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma [NCT05879367]Phase 166 participants (Anticipated)Interventional2023-07-24Recruiting
Clinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encepha [NCT00906880]Phase 4630 participants (Actual)Interventional2009-04-30Completed
A Randomized, Placebo-controlled, Double-blind, Phase II Chemoprevention Clinical Trial of Topical Diclofenac and DFMO in Subjects With a History of Skin Cancer [NCT04091022]Phase 2138 participants (Anticipated)Interventional2021-01-18Active, not recruiting
Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase [NCT00146627]Phase 3280 participants (Anticipated)InterventionalCompleted
A 24 Week Randomised Double Blind Placebo Controlled Study to Evaluate the Atrophogenic Potential of Eflornithine in the Treatment of Women With Excessive Facial Hair [NCT00152048]Phase 478 participants Interventional2004-11-30Completed
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With E [NCT01349881]Phase 3354 participants (Actual)Interventional2013-03-01Active, not recruiting
Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial [NCT00005884]Phase 30 participants InterventionalCompleted
A Randomized Double-Blind Study of Alpha-Difluromethylornithine (DFMO) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3 [NCT00006079]Phase 2150 participants (Actual)Interventional1998-06-19Completed
Randomized Placebo-Controlled, Double-Blind Phase IIb Chemoprevention Trial of Difluoromethylornithine in Brothers and First Cousin Males of Familial Prostate Cancer Probands [NCT00006101]Phase 276 participants (Actual)Interventional1998-10-31Completed
A Randomized Phase III Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP) [NCT01245816]Phase 30 participants (Actual)Interventional2011-03-31Withdrawn
TArgeting Type 1 Diabetes Using POLyamines (TADPOL): A Randomized, Double-Masked, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Difluoromethylornithine (DFMO) to Preserve Insulin Production in Type 1 Diabetes [NCT05594563]Phase 270 participants (Anticipated)Interventional2023-03-14Recruiting
A Randomized, Placebo-Controlled Phase IIb Clinical Trial of 2-Difluoromethylornithine (DFMO) Versus Bicalutamide (CASODEX) Alone and in Combination in Patients With Prostate Cancer in the Period Prior to Radical Prostatectomy or Brachytherapy: Modulation [NCT00086736]Phase 234 participants (Actual)Interventional2001-11-30Completed
Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase [NCT00330148]Phase 3435 participants Interventional2001-03-31Terminated
Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda [NCT00489658]Phase 2/Phase 331 participants (Actual)Interventional2002-10-31Terminated(stopped due to Because of unexpectedly reduced disease prevalence in the study area, a pragmatic decision was taken to terminate recruitment in March 2003.)
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 [NCT05717153]Early Phase 115 participants (Anticipated)Interventional2023-08-28Recruiting
Phase 2b Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients (OTR) [NCT00204789]Phase 252 participants (Anticipated)Interventional2003-07-31Completed
Phase IIB Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine (DFMO) With and Without a Topical Corticosteroid Cream (Triamcinolone 0.1%) in the Therapy of Actinic Keratoses (AK) on t [NCT00021294]Phase 20 participants Interventional2001-05-31Completed
Phase II, Open-Label Study of the Effect of 15% Eflornithine Hydrochloride Cream on Facial Hair of Men of African-American Descent With Pseudofolliculitis Barbae: A Laser Scanning Confocal Microscopy and Video Imaging Study [NCT00176995]Phase 215 participants Interventional1999-03-31Completed
Topical Eflornithine Hydrochloride for Pseudofolliculitis Barbae: A Randomized, Double-blinded, Placebo-controlled Trial [NCT04403282]Phase 425 participants (Anticipated)Interventional2020-07-31Not yet recruiting
Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label Study [NCT01685827]Phase 2/Phase 3394 participants (Actual)Interventional2012-10-31Completed
A Phase 2 Urinary Biomarker Study of Polyamine Inhibition With Sulindac and Difluoromethylornithine (DFMO) [NCT01636128]Phase 20 participants (Actual)Interventional2014-03-31Withdrawn(stopped due to Funding and staffing)
Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism [NCT01817894]Phase 422 participants (Actual)Interventional2012-01-31Completed
Phase IIb Chemoprevention Trial of Difluoromethylornithine (DFMO) in Human Subjects With Intestinal-type Barrett's Esophagus [NCT00003076]Phase 2152 participants (Anticipated)Interventional1995-10-31Completed
Phase III Randomized, Double-Blind Study of DFMO vs. Placebo in Low Grade Superficial Bladder Cancer [NCT00003814]Phase 3450 participants (Anticipated)Interventional1999-02-28Completed
A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Combination of DFMO and Sulindac to Decrease the Rate of Recurrence of Adenomatous Polyps in the Colon [NCT00118365]Phase 3375 participants (Actual)Interventional1998-07-31Completed
Phase I Dose-Finding, Safety Study of Oral AMXT 1501 Dicaprate and Difluoromethylornithine (DFMO) in Patients With Advanced Solid Tumors [NCT03536728]Phase 156 participants (Actual)Interventional2018-06-12Completed
Randomized Phase II Trial of Aspirin and Difluoromethylornithine (DFMO) in Patients at High Risk of Colorectal Cancer [NCT00983580]Phase 2107 participants (Actual)Interventional2009-08-20Completed
Phase III Trial of the Safety and Efficacy of Eflornithine Combined With Sulindac Compared to Eflornithine, Sulindac as Single Agents in Patients With Familial Adenomatous Polyposis [NCT01483144]Phase 3171 participants (Actual)Interventional2013-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00006101 (1) [back to overview]Change in Total PSA, Percent Free PSA, and Prostate Volume at 12 Months
NCT00033371 (3) [back to overview]Percent Change in the Number of Polyps Greater Than or Equal to 2mm in Diameter in Focal Area(s) of the Colorectum
NCT00033371 (3) [back to overview]Percentage Change in Global Colorectal Polyps Burden
NCT00033371 (3) [back to overview]Number of Participants With Adverse Events Occurring at a Frequency of 5% or Grade 3 and Higher
NCT00118365 (21) [back to overview]Detection of Any Adenoma at the End of the Study Stratified by Baseline Putrescine and Treatment
NCT00118365 (21) [back to overview]Detection of Any Adenoma at the End of the Study Stratified by Baseline Prostaglandin E2 (PGE2) and Treatment
NCT00118365 (21) [back to overview]Detection of Any Adenoma at the End of the Study
NCT00118365 (21) [back to overview]Biomarker in Adenoma: Sialyl-TN (B72.3)
NCT00118365 (21) [back to overview]Biomarker in Adenoma: CEA
NCT00118365 (21) [back to overview]Biomarker in Adenoma: Apoptosis
NCT00118365 (21) [back to overview]Biomarker in Adenoma: Bcl-2
NCT00118365 (21) [back to overview]At the End of the Study - Spermine Response by ODC Genotype
NCT00118365 (21) [back to overview]At the End of the Study - Spermidine Response by ODC Genotype
NCT00118365 (21) [back to overview]At the End of the Study - Putrescine Response by ODC Genotype
NCT00118365 (21) [back to overview]Number of Participants Have Adenoma Recurrence in Each ODC1 Genotytpe by Treatment Group
NCT00118365 (21) [back to overview]Biomarker in Adenoma - p53
NCT00118365 (21) [back to overview]Biomarker in Adenoma - Ki-67
NCT00118365 (21) [back to overview]Adverse Events With a Grade of 3 and Above
NCT00118365 (21) [back to overview]Baseline Putrescine by ODC Genotype
NCT00118365 (21) [back to overview]Baseline Spermidine by ODC Genotype
NCT00118365 (21) [back to overview]Baseline Spermine by ODC Genotype
NCT00118365 (21) [back to overview]Detection of Any Adenoma at the End of the Study Stratified by Baseline Spermidine-to-spermine Ratio and Treatment
NCT00118365 (21) [back to overview]Detection of Any Adenoma at the End of the Study Stratified by Prostaglandin E2 (PGE2) Response and Treatment
NCT00118365 (21) [back to overview]Detection of Any Adenoma at the End of the Study Stratified by Putrescine Response and Treatment
NCT00118365 (21) [back to overview]Detection of Any Adenoma at the End of the Study Stratified by Spermidine-to-spermine Ratio Response and Treatment
NCT00601640 (3) [back to overview]Change in Histologic Score Diagnosis and Treatment Group
NCT00601640 (3) [back to overview]Changes in Putrescine Over 3 Months
NCT00601640 (3) [back to overview]Safety of Combination Therapy With Topical Eflornithine Hydrochloride Ointment and Topical Diclofenac Sodium Gel Over 3-months
NCT00983580 (5) [back to overview]Characterization of ACF
NCT00983580 (5) [back to overview]Adenoma Recurrence Rate for the Treatment Arm Relative to Placebo
NCT00983580 (5) [back to overview]Comparison of the Percent Change in ACF Number Across the 2 Treatment Arms
NCT00983580 (5) [back to overview]ACF Characteristics vs Adenoma Recurrence Rate
NCT00983580 (5) [back to overview]Safety, Tolerability, and Adverse Events of Study Treatment
NCT01059071 (6) [back to overview]Progression Free Survival (PFS)
NCT01059071 (6) [back to overview]Number of Patients With an Overall Response Rate (ORR) of PR or CR
NCT01059071 (6) [back to overview]Number of Participants With Adverse Events as a Measure of Safety and Tolerability
NCT01059071 (6) [back to overview]Cmax of DFMO in Pediatrics Using Pharmacokinetic (PK) Testing.
NCT01059071 (6) [back to overview]AUC of DFMO in Pediatrics Using Pharmacokinetic (PK) Testing.
NCT01059071 (6) [back to overview]Tmax of DFMO in Pediatrics Using Pharmacokinetic (PK) Testing.
NCT01483144 (3) [back to overview]Improvement in Investigator Lower GI Assessment
NCT01483144 (3) [back to overview]Improvement in Investigator Upper GI Assessment
NCT01483144 (3) [back to overview]Number of Subjects With Any FAP-related Event.
NCT02395666 (7) [back to overview]Percentage of Participants With Overall Survival (OS)
NCT02395666 (7) [back to overview]Peak Plasma Concentration (Cmax)
NCT02395666 (7) [back to overview]Number of Participants With Event Free Survival (EFS) During Study.
NCT02395666 (7) [back to overview]Number of Participants With Adverse Events as a Measure of Safety and Tolerability
NCT02395666 (7) [back to overview]Area Under the Plasma Concentration Versus Time Curve (AUC)
NCT02395666 (7) [back to overview]Time to Reach Peak Plasma Concentration (Tmax)
NCT02395666 (7) [back to overview]Test the Association of Survival With ODC1 Genotype

Change in Total PSA, Percent Free PSA, and Prostate Volume at 12 Months

Difference refers to absolute difference of 12 months to baseline and % relative difference refers to the ratio of the absolute difference divided by the baseline times 100. (NCT00006101)
Timeframe: Baseline and 12 months

,
InterventionRelative % difference (Mean)
Total PSAPercent Free PSAProstate Volume
Eflornithine-0.7510.210.94
Placebo1.554.8911.14

[back to top]

Percent Change in the Number of Polyps Greater Than or Equal to 2mm in Diameter in Focal Area(s) of the Colorectum

Differences between average treatment effects of two study arms tested using two-sided type I error rate of 5% in two-sample t-test. If model assumptions not met by data or transformations of data, appropriate nonparametric tests (e.g. Wilcoxon rank sums test) were used to compare treatment arms - Percent change of polyp counts from baseline to 6 months, ie [(6 months - baseline) x 100]/baseline (%). For each participant, first were matched polyps between baseline & 6 months by region and landmark and summed over all matched regions on number of polyps >2 mm to calculate total number of polyps >2 mm at baseline & 6 months, respectively. For participants refusing exit colonoscopy, 0% change entered as primary endpoint. Defined ITT All: All patients; if 6-month polyp counts missing = 0% change; ITT Measurable: All participants with baseline & 6 month polyp counts; ITT Evaluable: ITT Measurable participants who also took 80% of treatment, both overall as well as during final 60 days. (NCT00033371)
Timeframe: Baseline up to 6 months

,
Interventionpercentage change in polyp count (Mean)
ITT AllITT MeasurableITT Evaluable
Arm I: Celecoxib and Placebo-1-110
Arm II: Celecoxib and Eflornithine-11-13-8

[back to top]

Percentage Change in Global Colorectal Polyps Burden

Percentage Change in Global Colorectal Polyps burden (NCT00033371)
Timeframe: 6 months

Interventionpercentage change of total Polyps burden (Mean)
Arm I: Celecoxib and Placebo-27
Arm II: Celecoxib and Eflornithine-40

[back to top]

Number of Participants With Adverse Events Occurring at a Frequency of 5% or Grade 3 and Higher

To determine the relative tolerability and safety of celecoxib + DFMO in FAP study participants. Includes only adverse events that occurred in at least 5% of the patients or a patient exhibited at least 1 grade 3 toxicity. (NCT00033371)
Timeframe: 6 months

,
InterventionParticipants (Count of Participants)
High-frequency hearing lossFatigueDiarrhoeaHeartburn/dyspepsiaMucositis/stomatitisNausea/vomitingGoutHeadache
Arm I:Celecoxib, 400 mg p.o. BID Plus DFMO Placebo ( 60 Partic4116411605
Arm II: Celecoxib, 400 mg p.o. BID Plus DFMO 0.5 gm/m2/Day Rou734215711

[back to top]

Detection of Any Adenoma at the End of the Study Stratified by Baseline Putrescine and Treatment

The low is defined as the values that are below the median putrescine level in the analysis cohort. The high is defined as the values that are above the median putrescine level in the analysis cohort. (NCT00118365)
Timeframe: Up 36 months

,,,
Interventionparticipants (Number)
YesNo
Eflornithine and Sulindac + High Putrescine at Baseline1056
Eflornithine and Sulindac + Low Putrescine at Baseline763
Placebo + High Putrescine at Baseline3136
Placebo + Low Putrescine at Baseline2438

[back to top]

Detection of Any Adenoma at the End of the Study Stratified by Baseline Prostaglandin E2 (PGE2) and Treatment

This analysis is based on the participants who had the end-of-study colonscopy procedure done and their baseline PGE2 values are available. The low PGE2 is defined as the values that are below the median PGE2 value in the analysis cohort. The high PGE2 is defined as the values that are above the median PGE2 value in the analysis cohort. (NCT00118365)
Timeframe: Up to 36 months

,,,
Interventionparticipants (Number)
YesNo
Eflornithine and Sulindac + High PGE2 at Baseline341
Eflornithine and Sulindac + Low PGE2 at Baseline1241
Placebo + High PGE2 at Baseline2132
Placebo + Low PGE2 at Baseline1923

[back to top]

Detection of Any Adenoma at the End of the Study

Detection of any adenoma at the end of the study. This analysis is based on the participants who had the end-of-study colonscopy procedure done. (NCT00118365)
Timeframe: Up to 36 months

,
Interventionparticipants (Number)
YesNo
Arm I (Eflornithine and Sulindac)17121
Arm II (Placebo)5376

[back to top]

Biomarker in Adenoma: Sialyl-TN (B72.3)

sialyl-Tn (B72.3) is adenocarcinoma tissue marker that is expressed during adenoma formation. (NCT00118365)
Timeframe: At the end of the study

,
InterventionAdenoma (Number)
a pattern equal to normal mucosa1.<10% of the cells in the adenoma showed staining2.10-50% cells showed staining3.>50% cells showed stainingInsufficient tissue
Arm I (Eflornithine and Sulindac)37200
Arm II (Placebo)11321751

[back to top]

Biomarker in Adenoma: CEA

carcino-embryonic antigen (CEA) is adenocarcinoma tissue marker that is expressed during adenoma formation. (NCT00118365)
Timeframe: At the end of the study

,
InterventionAdenoma (Number)
A pattern equal to normal mucosa1.<50% of cells showed staining2.50-90% of cells showed staining3.>90% of cells showed stainingInsufficient tissue
Arm I (Eflornithine and Sulindac)15600
Arm II (Placebo)5153592

[back to top]

Biomarker in Adenoma: Apoptosis

Apoptosis expression was assessed using cytoplasmic staining. The definitions for the category level for the Apoptosis are: 1. focal (less than 10% cells that are positively stained); 2. less than 50% cells are positively stained; 3. more than 50% cells are positively stained. (NCT00118365)
Timeframe: At the end of the study

,
Interventionadenoma (Number)
A pattern equal to normal mucosa1.focal (<10%)2.cyto less than 50%3.cyto more than 50%
Arm I (Eflornithine and Sulindac)2712
Arm II (Placebo)4202313

[back to top]

Biomarker in Adenoma: Bcl-2

bcl-2 is the anti-apoptotic protein BCL2 (NCT00118365)
Timeframe: At the end of the study, up to 3 years

,
InterventionAdenoma (Number)
A pattern equal to normal mucosa1.<10% of the cells in the adenoma showed staining2.10-50% cells showed staining3.>50% cells showed stainingInsufficient tissue
Arm I (Eflornithine and Sulindac)44310
Arm II (Placebo)17251482

[back to top]

At the End of the Study - Spermine Response by ODC Genotype

"Spermine responder was defined as (tissue spermine value at baseline - tissue spermine value at the end of the study)/(tissue spermine value at baseline) ≥ the threshold. Spermine non-responder was defined as (tissue spermine value at baseline - tissue spermine value at the end of the study)/(tissue spermine value at baseline) < the threshold. The thresholds range from 0.25 to 0.45 with an increment of 0.5. The below data are shown for the threshold of 0.30.~ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete." (NCT00118365)
Timeframe: At the end of the study

,,,
Interventionparticipants (Number)
ResponderNon-Responder
DFMO + Sulindac - AA/GA733
DFMO + Sulindac - GG751
Placebo - AA/GA1039
Placebo - GG1825

[back to top]

At the End of the Study - Spermidine Response by ODC Genotype

"Spermidine responder was defined as (tissue spermidine value at baseline - tissue spermidine value at the end of the study)/(tissue spermidine value at baseline) ≥ the threshold. Spermidine non-responder was defined as (tissue spermidine value at baseline - tissue spermidine value at the end of the study)/(tissue spermidine value at baseline) < the threshold. The thresholds range from 0.25 to 0.45 with an increment of 0.5. The below data are shown for the threshold of 0.30.~ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete." (NCT00118365)
Timeframe: At the end of the study

,,,
Interventionparticipants (Number)
ResponderNon-Responder
DFMO + Sulindac - AA/GA1228
DFMO + Sulindac - GG2532
Placebo - AA/GA1138
Placebo - GG1528

[back to top]

At the End of the Study - Putrescine Response by ODC Genotype

"Putrescine responder was defined as (tissue putrescine value at baseline - tissue putrescine value at the end of the study)/(tissue putrescine value at baseline) ≥ the threshold. Putrescine non-responder was defined as (tissue putrescine value at baseline - tissue putrescine value at the end of the study)/(tissue putrescine value at baseline) < the threshold. The thresholds range from 0.25 to 0.45 with an increment of 0.5. The below data are shown for the threshold of 0.30.~ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete." (NCT00118365)
Timeframe: At the end of the study

,,,
Interventionparticipants (Number)
ResponderNon-Responder
DFMO + Sulindac - AA/GA2119
DFMO + Sulindac - GG2632
Placebo - AA/GA1237
Placebo - GG1231

[back to top]

Number of Participants Have Adenoma Recurrence in Each ODC1 Genotytpe by Treatment Group

ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete. (NCT00118365)
Timeframe: Up to 36 months

Interventionparticipants (Number)
DFMO + Sulindac - GG7
DFMO + Sulindac - AA/GA9
Placebo - GG22
Placebo - AA/GA18

[back to top]

Biomarker in Adenoma - p53

"Estimated mean percent of cells staining postivie for p53 based on GEE approach with adjument for covariates.~Tumor protein p53, also known as p53, cellular tumor antigen p53, phosphoprotein p53, or tumor suppressor p53, is a protein that in humans is encoded by the TP53 gene." (NCT00118365)
Timeframe: At the end of the study

Interventionpercentage of cells that are positive (Mean)
Arm I (Eflornithine and Sulindac)75.6
Arm II (Placebo)70.3

[back to top]

Biomarker in Adenoma - Ki-67

Estimated mean percent of cells staining postivie for the Ki-67 based on the GEE approach with adjustment for covariates (NCT00118365)
Timeframe: At the end of the study

Interventionpercentage of cells that are positive (Mean)
Arm I (Eflornithine and Sulindac)59.5
Arm II (Placebo)63.9

[back to top]

Adverse Events With a Grade of 3 and Above

"Participants reported at least 1 adverse event with a grade of 3 and above, regardless if the event is defined as serious per protocol or other.~Per protocol, not all grade 3 events are considered as serious events." (NCT00118365)
Timeframe: Up to 36 months

Interventionparticipants (Number)
Arm I (Eflornithine and Sulindac)46
Arm II (Placebo)37

[back to top]

Baseline Putrescine by ODC Genotype

ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete. (NCT00118365)
Timeframe: Baseline

Interventionnmol/mg protein (Median)
ODC1 AA/GA0.47
ODC1 GG0.56

[back to top]

Baseline Spermidine by ODC Genotype

ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete. (NCT00118365)
Timeframe: Baseline

Interventionnmol/mg protein (Median)
ODC1 AA/GA1.99
ODC1 GG2.17

[back to top]

Baseline Spermine by ODC Genotype

ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete. (NCT00118365)
Timeframe: Baseline

Interventionnmol/mg protein (Median)
ODC1 AA/GA6.82
ODC1 GG7.29

[back to top]

Detection of Any Adenoma at the End of the Study Stratified by Baseline Spermidine-to-spermine Ratio and Treatment

"The low is defined as the ratios that are below the median spermidine-to-spermine ratio in the analysis cohort. The high is defined as the ratios that are above the median spermidine-to-spermine ratio in the analysis cohort.~In the finalized datasaet, the total number of adnoma detected in the placebo group is 55. The descrepancy in the total number of adnoma detected in placebo group between Outcome Measure 1 and this oucome is due to the revolution of the datatset.~The analysis cohort is based on the participants whose data are available and complete." (NCT00118365)
Timeframe: Up 36 months

,,,
Interventionparticipants (Number)
YesNo
Eflornithine and Sulindac + High Spd:Spm at Baseline1260
Eflornithine and Sulindac + Low Spd:Spm at Baseline559
Placebo + High Spd:Spm at Baseline2437
Placebo + Low Spd:Spm at Baseline3137

[back to top]

Detection of Any Adenoma at the End of the Study Stratified by Prostaglandin E2 (PGE2) Response and Treatment

PGE2 Responder = PGE2 values at 36-month are decreased by >=30% in PGE2 values from baseline PGE2 nonresponder = PGE2 values at 36-month are increased, or decreased by < 30% from baseline The analysis cohort is based on the participants whose data are available and complete. (NCT00118365)
Timeframe: Up to 36 months

,,,
Interventionparticipants (Number)
YesNo
Eflornithine and Sulindac + PGE2 Nonresponders827
Eflornithine and Sulindac + PGE2 Responders110
Placebo + PGE2 Nonresponders1517
Placebo + PGE2 Responders413

[back to top]

Detection of Any Adenoma at the End of the Study Stratified by Putrescine Response and Treatment

Putrescine responder = Putrescine values at 36-month are decreased by >=30% from baseline Putrescine nonresponder = Putrescine values at 36-month are increased, or decreased by < 30% from baseline The analysis cohort is based on the participants whose data are available and complete. (NCT00118365)
Timeframe: Up to 36 months

,,,
Interventionparticipants (Number)
YesNo
Eflornithine and Sulindac + Putrescine Nonresponders753
Eflornithine and Sulindac + Putrescine Responders952
Placebo + Putrescine Nonresponders2844
Placebo + Putrescine Responders2224

[back to top]

Detection of Any Adenoma at the End of the Study Stratified by Spermidine-to-spermine Ratio Response and Treatment

Spermidine-to-spermine ratio responder = ratios at 36-month are decreased by >=30% from baseline Spermidine-to-spermine ratio nonresponder = ratios at 36-month are increased, or decreased by < 30% from baseline The analysis cohort is based on the participants whose data are available and complete. (NCT00118365)
Timeframe: Up to 36 months

,,,
Interventionparticipants (Number)
YesNo
Eflornithine and Sulindac + Spd:Spm Nonresponders830
Eflornithine and Sulindac + Spd:Spm Responders875
Placebo + Spd:Spm Nonresponders3344
Placebo + Spd:Spm Responders1724

[back to top]

Change in Histologic Score Diagnosis and Treatment Group

Change scores were computed by subtracting baseline histologic score from End of Study histologic score. Slides were formalin fixed. Histologic Score has been developed by this research group over the course of Grant (reference below). A standardized form captures data on the following criteria: basal or suprabasilar pleomorphism (atypia); inflammation; hyperkeratosis; parakeratosis. The atypia and inflammation were rated as: none (0), mild to moderate(1), and severe (2). The remaining criteria were rated as present (1) or absent (0). Histologic Scores were computed by adding together the codes for the histologic criteria. Higher scores reflected higher level of epidermal /dermal damage. (NCT00601640)
Timeframe: 3 months

Interventionunits on a scale (Mean)
Eflornithine Hydrochloride0.33
Diclofenac Sodium0.26
Eflornithine Hydrochloride/Diclofenac Sodium0.64

[back to top]

Changes in Putrescine Over 3 Months

Putrescine is measured in nmole/g skin per biopsy. Baseline and End of Study biopsies were measured and the change was produced by subtracting baseline levels from End of Study levels. There was one baseline biopsy and one End of Study biopsy per participant. (NCT00601640)
Timeframe: 3 months

Interventionnmol/g skin (Mean)
Eflornithine Hydrochloride0.03
Diclofenac Sodium1.45
Eflornithine Hydrochloride/Diclofenac Sodium0.2

[back to top]

Safety of Combination Therapy With Topical Eflornithine Hydrochloride Ointment and Topical Diclofenac Sodium Gel Over 3-months

Adverse events were compared across three treatment groups by severity determined by the clinician. All adverse events were resolved by the end of follow up. (NCT00601640)
Timeframe: 3 months

,,
Interventionparticipants (Number)
Burning and Stinging NoneBurning and stinging Mildburning and stinging ModerateBurning and Stinging SeverePruritis NonePruritis MildPruritis ModeratePruritis SevereRash, Redness. Erythema-NoneRash, Redness. Erythema-MildRash, Redness. Erythema-ModerateRash, Redness. Erythema-Severe
Diclofenac Sodium44800331261341080
Eflornithine Hydrochloride484004291046510
Eflornithine Hydrochloride/Diclofenac Sodium483104066040750

[back to top]

Characterization of ACF

A potential surrogate endpoint biomarker is the aberrant crypt focus (ACF). ACF are the earliest lesions that can be detected in colorectal mucosa and are believed to be precursors of adenomas and cancers. The number and total size of ACF sites may serve as risk markers for adenoma/carcinoma development. The median number of ACF sites per patient were collected prior to treatment. (NCT00983580)
Timeframe: Baseline

Interventionnumber of ACF sites (Median)
Arm I (Acetylsalicylic Acid and Eflornithine)11
Arm II (Placebo)7

[back to top]

Adenoma Recurrence Rate for the Treatment Arm Relative to Placebo

The primary endpoint is the proportion of participants with an adenoma recurrence at the 1-year follow-up colonoscopy exam. All eligible, randomized participants who have signed a consent form and received at least one follow-up endoscopy exam will be considered evaluable for the primary endpoint. This adenoma recurrence rate for DFMO + aspirin will be compared to double placebo to see if there is improvement in the adenoma recurrence rate in this patient population. A 1-sided Chi-square test was used to determine if there was a significant difference between treatment arms. (NCT00983580)
Timeframe: At 1 year

Interventionproportion of participants (Number)
Arm I (Acetylsalicylic Acid and Eflornithine)0.595
Arm II (Placebo)0.581

[back to top]

Comparison of the Percent Change in ACF Number Across the 2 Treatment Arms

The number of ACF sites per patient was collected at baseline and at 1-year time points. The percent change in ACF number was calculated as the number of ACF present at the 12-month post-intervention exam minus the baseline number of ACF, divided by the number of ACF present at baseline. A negative score represents a loss in the number of sites from baseline to year 1 post-treatment. A positive number indicates an increase in the number of ACF sites. Therefore, the possible range in percent change cannot be lower than -100% and has no upper bound. The percent change in ACF number between arms was compared using a t-test. (NCT00983580)
Timeframe: At baseline and 12 months

Interventionpercentage of change in ACF number (Mean)
Arm I (Acetylsalicylic Acid and Eflornithine)-28.6
Arm II (Placebo)10.6

[back to top]

ACF Characteristics vs Adenoma Recurrence Rate

A potential surrogate endpoint biomarker is the aberrant crypt focus (ACF). ACF are the earliest lesions that can be detected in colorectal mucosa and are believed to be precursors of adenomas and cancers. At the 1-year time point, the presence of adenoma recurrence and the number of ACF sites was recorded for each patient. The percent change in ACF number was calculated as the number of ACF present at the 1-year post-intervention exam minus the baseline number of ACF, divided by the number of ACF present at baseline. A negative score represents a loss in the number of sites and a positive number indicates an increase in the number of ACF sites. Therefore, the possible range in percent change cannot be lower than -100% and has no upper bound. A Wilcoxon Rank-sum test was used to assess the relationship between ACF percent change and adenoma recurrence rate. This analysis was only conducted in those participants who had at least 5 rectal ACF at baseline. (NCT00983580)
Timeframe: At baseline and 1 year

Interventionpercentage of change in ACF number (Median)
No Adenoma Recurrence at 12 monthsAdenoma Recurrence at 12 months
All Patients-20.8-45.0

[back to top]

Safety, Tolerability, and Adverse Events of Study Treatment

The National Cancer Institute (NCI) Common Terminology Criteria (CTC) Version 3.0 was used to grade all adverse events. The number of patients reporting a grade 3 or higher event are tabulated here. A grade 3 event is one categorized as being severe or medically significant but not immediately life-threatening. A grade 4 is considered life-threatening, and a grade 5 is death related to the event. A complete list of all adverse events is given in the Adverse Events section. (NCT00983580)
Timeframe: Up to 48 months from beginning treatment.

,
InterventionParticipants (Count of Participants)
Grade 3 Adverse EventGrade 4 Adverse Event
Arm I (Acetylsalicylic Acid and Eflornithine)00
Arm II (Placebo)30

[back to top]

Progression Free Survival (PFS)

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT01059071)
Timeframe: 2 years

InterventionDays (Median)
DFMO and Etoposide85

[back to top]

Number of Patients With an Overall Response Rate (ORR) of PR or CR

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT01059071)
Timeframe: 1 year

Interventionparticipants (Number)
DFMO and Etoposide4

[back to top]

Number of Participants With Adverse Events as a Measure of Safety and Tolerability

To determine the safety, tolerability and maximum tolerated dose (MTD) of DFMO as a single agent and in combination with etoposide in pediatric and young adult patients with refractory or recurrent neuroblastoma (NCT01059071)
Timeframe: length of study plus 30 days

Interventionparticipants (Number)
Dose Level 1: 500 mg/m2 PO BID2
Dose Level 2: 750 mg/m2 PO BID4
Dose Level 3:1000 mg/m2 PO BID0
Dose Level 4:1500 mg/m2 PO BID5

[back to top]

Cmax of DFMO in Pediatrics Using Pharmacokinetic (PK) Testing.

(NCT01059071)
Timeframe: Cycle 1 Day 8 at hour 0 (pre-dose), 30 minutes, 1 hour, 3 hours, and 6 hours

Interventionmcg/ml (Mean)
DFMO and Etoposide28.89

[back to top]

AUC of DFMO in Pediatrics Using Pharmacokinetic (PK) Testing.

(NCT01059071)
Timeframe: Cycle 1 Day 8 at hour 0 (pre-dose), 30 minutes, 1 hour, 3 hours, and 6 hours

Intervention(mcg/ml) * hr (Mean)
DFMO and Etoposide108.38

[back to top]

Tmax of DFMO in Pediatrics Using Pharmacokinetic (PK) Testing.

(NCT01059071)
Timeframe: Cycle 1 Day 8 at hour 0 (pre-dose), 30 minutes, 1 hour, 3 hours, and 6 hours

Interventionhours (Mean)
DFMO and Etoposide2.88

[back to top]

Improvement in Investigator Lower GI Assessment

Global assessment of change in lower GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint. (NCT01483144)
Timeframe: through month 12 assessment

,,
InterventionParticipants (Count of Participants)
ImprovedNot Improved
Eflornithine Plus Sulindac2234
Eflornithine Plus Sulindac Placebo1641
Sulindac Plus Eflornithine Placebo2236

[back to top]

Improvement in Investigator Upper GI Assessment

Global assessment of change in upper GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint. (NCT01483144)
Timeframe: through month 12 assessment

,,
InterventionParticipants (Count of Participants)
ImprovedNot Improved
Eflornithine Plus Sulindac1145
Eflornithine Plus Sulindac Placebo1047
Sulindac Plus Eflornithine Placebo1048

[back to top] [back to top]

Percentage of Participants With Overall Survival (OS)

To evaluate the preventative activity of DFMO as a single agent in patients with neuroblastoma who are in remission based on: Overall Survival (OS) (NCT02395666)
Timeframe: 2 Years

Interventionpercentage of subjects without an event (Mean)
Stratum 197
Stratum 284

[back to top]

Peak Plasma Concentration (Cmax)

"Pharmacokinetic assay Cmax/D~Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days." (NCT02395666)
Timeframe: Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days

Interventionng/mL (Mean)
Study Subjects Consented to PK Collection11958

[back to top]

Number of Participants With Event Free Survival (EFS) During Study.

To evaluate the preventative activity of DFMO as a single agent in patients that are in remission based on: Event free survival (EFS) (NCT02395666)
Timeframe: 2 Years

Interventionpercentage of subjects without an event (Mean)
Stratum 184
Stratum 251

[back to top]

Number of Participants With Adverse Events as a Measure of Safety and Tolerability

To continue to determine the safety and tolerability of DFMO as a single agent and in pediatric and young adult patients with high risk neuroblastoma that is in remission. (NCT02395666)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
DFMO Twice Daily57

[back to top]

Area Under the Plasma Concentration Versus Time Curve (AUC)

"Pharmacokinetic assay AUC(0-6 hr)/D~Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days" (NCT02395666)
Timeframe: 0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose on two different days

Interventionhr*ng/mL (Mean)
Study Subjects Consented to PK Collection47024

[back to top]

Time to Reach Peak Plasma Concentration (Tmax)

"Pharmacokinetic assay- tmax, hr~Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days" (NCT02395666)
Timeframe: 0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose on two different days

Interventionhours (Mean)
Study Subjects Consented to PK Collection3.3

[back to top]

Test the Association of Survival With ODC1 Genotype

"Tests (p-value) of the association of survival with ODC1 single nucleotide polymorphism rs2302616 genotype.~Blood: microRNA analysis as predictor of DFMO effect, ornithine decarboxylase (ODC) single nucleotide polymorphism (SNP) analysis in DNA isolated from nucleated cells" (NCT02395666)
Timeframe: 2 years

Interventionp-value (Number)
GG, GT, TT0.96
GG or GT, TT0.58
GG, GT or TT0.67

[back to top]